

# index

## A

AACPI, 2

Abdominal pain

cancer-related, 534*t*

Crohn's disease and, 597–598

Absorption, drug

elderly and, 687, 688

intraspinal local anesthetics and, 228

of opioid, 167–169, 168*f*

rectal, 204

Abstinence syndrome, 609, 616–617

nalbuphine causing, 614

Abuse

elder, 706

substance, 428–462; *see also* Addiction

Accountability for pain management, 3–4, 730, 733

Accreditation, 730, 733

Acetaminophen

antihistamines with, 150

aspirin with, 148–149

breast feeding and, 623

caffeine with, 316

clinical considerations for, 108–110

combination drugs with, 116–117, 134

definition of, 130

dosage of, 139*t*

for child, 143*t*

frequency, 139–140*t*, 140–141

guidelines for, 142

opioid equivalent, 133*t*

titration of, 141

elderly and, 690

equianalgesic dosage of, 133*t*

hemophilia and, 599

indications for, 131–134

infant and, 653–654

mechanism of action of, 130

nonprescription formulations of, 148*t*

Acetaminophen—cont'd

nonsteroidal antiinflammatory drugs versus, 104

overdose of, 151–152

pregnancy and, 611, 613

preparations of, 148*t*

as rectal suppository, 150*t*

safety of, 110

side effects of, 134–136

tension headache and, 558

Acetic acid derivative, 139*t*

Acetylsalicylic acid; *see also* Aspirin

infant and, 654

migraine and, 554*t*

Acquired immunodeficiency syndrome, 564–568, 566*f*

peripheral neuropathy and, 576

Action potential

definition of, 16

nociception and, 19*t*

transduction of pain and, 18

Action stage of drug treatment, 448

Action sites, analgesic, 106–107*f*

Acupuncture for fibromyalgia, 549

Acute pain model

adaptation versus, 43–45

correction of, 45–46

Acute pain services, 11

Acute versus chronic pain, 493–494; *see also* Pain *entries*

Adaptation model, 43–46

Addiction

challenges of, 462

definition of, 36, 50–51, 162, 429, 433–436

discussing with patient and family, 275–276*t*

drugs of abuse and, 432–433, 432*t*, 433*t*

elderly and, 705–706

family's fear of, 10

infant and, 631

as label, 51, 53–54

memory of pain and, 30

misconceptions about, 52–53*t*, 276*t*, 430*t*, 439–440

misinterpretation of, 173–174

models of, 431–432, 431*t*

*t* after a page number indicates a table, box, or form; *f* after a page number indicates an illustration.

- Addiction—cont'd
- to opioid, 173–174
    - undertreatment of pain and, 9
  - pain management in, 450–462, 455*t*, 460*t*
    - chronic pain and, 461–462, 477
    - clinical principles in, 453–454
    - inpatient, 454–456, 461*t*
    - naltrexone and, 460–461
    - outpatient, 456, 458
    - overlap between, 452–453
    - recovery from addiction and, 459–460
  - patient information about, 275–276*t*
  - patient placement and, 451, 451*t*
  - phenomenology of, 436–440
  - response documentation, 459*t*
  - treatment of, 440–450
    - characteristics of, 441
    - cognitive-behavioral, 445–446
    - commonalties in, 446
    - detoxification and, 441–442
    - drugs used in, 442*t*, 443–445
    - referral for, 446–450
    - residential, 446
    - twelve-step, 442–443
    - written agreement for, 754–755
- Adenocard; *see* Adenosine
- Adenoscan; *see* Adenosine
- Adenosine, 339
- Adenosine triphosphate, 22
- Adhesive, tissue, 395
- Adjuvant analgesics, 105*f*, 302–353
  - for acute pain, 335–340
  - alcohol as, 334–335
  - alpha<sub>2</sub>-adrenergic agonists as, 313–314
  - antidepressants as, 306–311, 306*t*; *see also* Antidepressants
  - antihistamines as, 334
  - benzodiazepines as; *see* Benzodiazepine
  - breast feeding and, 623–624
  - caffeine as, 315–316
  - cannabinoids as, 334
  - in children, 340, 341*t*
  - for chronic pain
    - bone, 324–326, 325*t*
    - classes of, 305*t*
    - lancinating, 320–324
    - multipurpose drugs for, 306–317
    - musculoskeletal, 327–328, 327*t*
    - neuropathic, 317–320, 317*t*, 328–332
  - classifications, 304*t*
    - major, 305*t*
  - clinical considerations for, 112–113
  - cocaine as, 316
  - combination analgesics with, 116
  - comparison of, 114*f*, 115
  - corticosteroids as, 311–313
  - definition of, 104, 162
  - dextroamphetamine as, 314–315
  - dosage of, 341–344*t*
  - elderly and, 695–698
  - examples of, 109*t*
- Adjuvant analgesics—cont'd
  - general considerations in, 303–306
  - guidelines for use, 342–344*t*
  - indications for, 316–317
  - local anesthetics as, 316
  - for malignant bone pain, 325*t*
  - for malignant bowel obstruction, 327*t*
  - methylphenidate as, 314–315
  - misconceptions about, 303*t*
  - neuroleptics as, 316–317, 332–334
  - NMDA receptor blockers as, 317
  - pain mechanism affected by, 108
  - patient information about, 340, 345–353*t*
  - pediatric dosing, 341*t*
  - pregnancy and, 614–615
  - reflex sympathetic dystrophy and, 583
  - temporomandibular dysfunction and, 590
  - titration of, 122
- Administration of analgesic; *see* Route of administration; *specific route*
- Administrative rules on pain management, 738
- Admission assessment of pain, 58–59, 59*t*
- Adrenocorticotrophic hormone, pain and, 24
- Adult protective services, 706
- Adverse drug effects
  - elderly and, 689
  - fetal, 621
  - HIV and, 566–567
  - infant and, 655
- Advil; *see* Ibuprofen
- Afferent neuron, 16
- Age
  - elderly and, 674–706; *see also* Elderly patient
  - infant and, 629–669; *see also* Infant
  - opioid and, 192
  - pain assessment and, 57
  - shingles and, 561
- Agency for Health Care Policy and Research
  - clinical practice guidelines of, 7, 43–44
  - education of clinicians and, 89
  - low back pain and, 600
  - nondrug pain treatment and, 423
  - patient education materials of, 274
  - quality improvement and, 713
  - undertreatment of pain and, 2
- Aggregation, platelet, 138, 144
- Agitation in alcohol withdrawal, 457
- Agonist, mu; *see* Mu agonist
- Agonist-antagonist
  - buprenorphine, 188
  - butorphanol, 188–189
  - characteristics of, 188–190
  - clinical considerations for, 112
  - combination analgesics with, 116
  - comparison of, 114
  - definition of, 162, 363
  - dezocine, 189
  - examples of, 109*t*
  - intranasal administration of, 203
  - labor and delivery and, 618

- Agonist-antagonist—cont'd  
 mild pain and, 191  
 misconceptions about, 163*t*  
 mu agonist with, 112  
 nalbuphine, 189  
 opioid receptor sites and, 166  
 pentazocine, 189–190  
 pruritus and, 265–266
- Agreement, written, 751–752
- AHCPR; *see* Agency for Health Care Policy and Research
- AIDS, 564–568, 566*f*  
 peripheral neuropathy and, 576
- Alcohol addiction, 432*t*  
 CAGE questionnaire about, 705  
 elderly and, 705–706  
 pharmacologic effects and, 432  
 psychiatric disorders with, 436–437, 436*t*, 437*t*  
 treatment of, 445  
 withdrawal assessment and, 457*t*
- Alcohol as adjuvant analgesic, 334–335
- Alcoholics Anonymous, 442–443, 442*t*
- Aleve; *see* Naproxen
- Algorithm for infant care, 662–663*f*
- Alka-Seltzer, 148*t*
- Allergy  
 aspirin, 144  
 intraspinal local anesthetics and, 228  
 nonsteroidal antiinflammatory drug and, 110  
 opioids and, 193
- Allodynia, 302  
 definition of, 16  
 herpes zoster and, 562
- Alpha<sub>2</sub>-adrenergic agonist  
 clonidine; *see* Clonidine  
 examples of, 305*t*  
 indications and dosages of, 342*t*  
 neuropathic pain and, 321*t*
- Alpha<sub>1</sub>-blocker for postmastectomy pain, 604
- Alzheimer's disease, 675
- Ambulatory surgery, 145
- Amerge; *see* Naratriptan
- Americaine; *see* Benzocaine
- American Academy of Head, Facial and Neck Pain, and  
 TMJ Orthopedics, 516
- American Academy of Hospice and Palliative Medicine, 13
- American Academy of Pain Medicine, 11
- American Academy of Physical Medicine and Rehabilitation, 516
- American Alliance of Cancer Pain Initiatives, 2, 11
- American Amputee Foundation, 516
- American Board of Internal Medicine, 6
- American Board of Pain Medicine, 516
- American Burn Association, 527
- American Chiropractic Association, 516
- American Chronic Pain Association, 516
- American College of Emergency Physicians  
 clinical practice guidelines of, 7  
 unknown cause of pain and, 47
- American Foundation for Pain Research, 516
- American Pain Society, 516–517  
 acute pain model and, 43–44  
 American Pain Society—cont'd  
 clinical practice guidelines of, 7  
 definition of pain and, 16  
 education of clinicians and, 89  
 founding of, 11  
 home page, 747*f*  
 pain care committee and, 715  
 patient-controlled analgesia, 249  
 quality improvement and, 713  
 unknown cause of pain and, 47  
 web site of, 747*f*
- American Society of Addiction Medicine, 461
- American Society of Clinical Oncology, 6
- American Society of Pain Management Nurses, 517  
 certification and, 11, 13  
 founding of, 11  
 placebo and, 55–56
- Amethocaine, 376
- Amitriptyline, 305*t*, 306*t*  
 as adjuvant analgesic, 306  
 breast feeding and, 623–624  
 for child, 341*t*  
 dosage of, 343*t*  
 elderly and, 696–697, 699*t*  
 fibromyalgia and, 548  
 indications for, 310  
 tension headache and, 555*t*
- Amphetamine, 193
- Amputation, 257–258  
 pain after, 603–604  
 phantom limb pain after  
 in elderly, 694  
 previous acute pain and, 30–31
- Anacin, 149*t*
- Anafranil; *see* Clomipramine
- Analgesia; *see also* Analgesics  
 balanced; *see* Balanced analgesia  
 conscious, 382–384*t*  
 epidural; *see* Epidural analgesia  
 intraspinal; *see* *Intraspinal analgesia*  
 masking diagnostic information with, 47  
 optimization of, 122–123  
 overview of, 103–128  
 patient-controlled; *see* Patient-controlled analgesia  
 preemptive; *see* Preemptive analgesia  
 principles of, 121–123  
 procedures requiring, 365*t*
- Analgesics  
 action sites, 106–107*f*  
 adjuvant; *see* Adjuvant analgesic  
 “Andrew-Robert survey” and, 38*t*, 40  
 assessment of, 38*t*  
 combined; *see* Combination analgesics  
 combining, 105*t*, 116*t*  
 differential diagnosis, 172*t*  
 formulary guide, 737*t*  
 by infusion; *see also* Infusion  
 flow sheet for, 79–80*t*, 83–86*t*  
 groups and subgroups, 105*t*, 109*t*  
 comparisons of, 114*t*

- Analgesics—cont'd
- list of, 125*t*
  - nonopioid, 129–159; *see also* Acetaminophen; Nonsteroidal antiinflammatory drug
  - nonprescription, 148–149*t*
  - nurses response to survey, 40*t*
  - opioid; *see* Opioid analgesic
  - pregnancy misconceptions, 610*t*
  - patient controlled, 754*t*
  - outpatient opioids, 755*t*
  - topical, 331*t*; *see also* Topical agents
  - use of, 38*t*
    - during pregnancy, childbirth, postpartum, and breast feeding, 608–625
- Analgesic ceiling
- definition of, 104, 130, 162, 363
  - elderly and, 690
- Analgesic groups, 104–128
- Analgesic ladder, WHO, 115–119, 117*f*
- Anaprox; *see* Naproxen
- “Andrew-Robert” survey, 38*t*, 40*t*
- nurses’ expectations about pain and, 44
- Anecdotal evidence, 302
- Anemia, sickle cell, 585–588
- Anesthesia
- action sites, 319*f*
  - circumcision and, 636–637
  - epidural; *see* Epidural analgesia
  - general, 386–389, 387*t*
  - local; *see* Local anesthetic
  - low back pain and, 600
  - nerve block records and, 511–512*t*
- Aneurysm, aortic, 26
- Angiography, back pain from, 391
- Animal, companion, for relaxation, 421
- Ankylosing spondylitis, 595–596
- Antacid
- misconceptions about, 131*t*
  - prevention of ulcers and, 137
- Antagonist, 162
- opiod, inappropriate use, 269
- Antenatal period, 609
- Anterior deltoid trigger point, 571*f*
- Antiarrhythmic agent for temporomandibular dysfunction, 590
- Anticholinergic agent
- antidepressants as, 308
  - elderly and, 695, 697
  - malignant bowel obstruction and, 327, 327*t*
  - opioids and, 193
- Anticonvulsants
- action sites, 319*f*
  - adverse effects of, 322–324
  - breast feeding and, 624
  - carbamazepine and, 321
  - clonazepam and, 322
  - dosage for, 324
  - elderly and, 697
  - examples of, 305*t*
  - gabapentin and, 322
  - herpes zoster and, 562
- Anticonvulsants—cont'd
- indications and dosages of, 342*t*
  - lamotrigine and, 322
  - mechanism of, 322
  - migraine and, 555*t*
  - neuropathic pain and, 321*t*
  - peripheral neuropathy and, 578
  - phenytoin and, 321–322
  - pregnancy and, 615
  - temporomandibular dysfunction and, 590
  - valproic acid and, 322
- Antidepressants
- action sites of, 309*f*
  - analgesics, 306*t*
    - adjuvant, 306*t*
    - action sites, 309*f*
  - breast feeding and, 623–624
  - for child, 341*t*
  - for chronic pain, 306–311
    - adverse effects of, 308–310
    - amitriptyline and, 306
    - clomipramine and, 307
    - desipramine and, 307
    - dosage of, 310–311
    - doxepin and, 307
    - imipramine and, 306–307
    - indications for, 310
    - mechanism of action of, 308
    - monitoring of, 311
    - newer, 307
    - nortriptyline and, 307
    - selection of, 310
  - elderly and, 696–697, 699*t*
  - fibromyalgia and, 548
  - herpes zoster and, 562
  - misconceptions about, 303*t*
  - neuropathic pain and, 317, 317*t*, 321*t*
  - osteoporosis and, 575
  - pregnancy and, 614–615
  - temporomandibular dysfunction and, 590
  - tricyclic
    - in elderly, 696–697
    - examples of, 306
    - indications and dosages of, 343*t*
    - modulation of pain and, 23
    - opioids and, 193
    - peripheral neuropathy and, 578
    - postmastectomy pain and, 604
    - tension headache and, 555*t*
- Antidiuretic hormone, 24
- Antihistamine
- as adjuvant analgesic, 334
  - elderly and, 695
  - nonopioids with, 150
  - opioids and, 193
- Antiinflammatory drug, nonsteroidal, 129–159; *see also* Non-steroidal antiinflammatory drug
- Antiparkinsonian drug, 193
- Antipyretic, 144; *see also* Aspirin; Nonsteroidal antiinflammatory drug

- Antisocial personality, 436
- Antiviral agent  
herpes zoster and, 563  
HIV and, 565
- Anxiety  
alcohol addiction and, 436  
withdrawal from, 457  
burn injury and, 529*t*  
as cause of pain, 48–49  
chronic pain and, 500  
definition of, 468  
reducing, 390*t*
- Aortic aneurysm, 26
- APAP, 138*t*, 148*t*, 150*t*
- Aphthous ulcer in HIV, 566–567
- Appliance for temporomandibular dysfunction, 590
- Arachnoiditis, 596
- Around the clock dosing, 175  
cognitively impaired elderly and, 704  
rescue dose and, 244–246
- Arteritis, temporal, 695–696
- Artery, coronary, bypass of, 694
- Arthriten, 149*t*
- Arthritis, 523–527, 524*f*, 525*f*  
alternative treatment for, 690*t*  
in child, 143*t*
- Arthritis Foundation Aspirin Free, 148*t*
- Arthropan; *see* Choline salicylate
- Artificial saliva, 602
- ASA; *see* Aspirin
- Aseptic necrosis, 539
- Aspirin  
acetaminophen with, 148–149  
allergy or intolerance to, 144  
bleeding and, 135, 138  
buffered, 149  
dosage of, 139*t*  
for child, 143*t*  
equianalgesic dosage of, 133*t*  
indications for, 131  
infant and, 654  
nonprescription formulations of, 148–149*t*  
overdose of, 150–151, 152  
pediatric dosage of, 143*t*  
renal function and, 136  
topical, 332
- Aspirin Free Maximum Strength, 148*t*
- Aspirin Free Pain Relief, 148*t*
- Assessment, 36–99, 123  
addiction and, 461  
admission, 58–59, 59*t*  
of analgesic history, 124*t*, 125*t*  
arachnoiditis and, 596  
behavioral responses, 43–45, 95*t*  
challenges in, 89, 92–99  
chronic pain and, 477–486, 492–493, 508–509  
complexities of, 36–39  
Crohn's disease and, 598  
elderly and, 686–687  
epidural anesthesia, 230–231*t*
- Assessment—cont'd  
failure to attain, 36–38  
of headache, 550, 552  
herpes zoster and, 562  
initial, 58–62, 60*f*, 61*f*  
institutional needs, 724–726  
lack of accountability for pain and, 3–4  
low back pain and, 599–600  
misconceptions affecting, 37*t*, 39–58  
addiction and, 50–54  
authority about pain and, 39–42  
clinician's expectations and, 44–46  
implications of, 56–58  
know versus unknown cause of pain and, 46–50  
pain threshold and, 42  
pain tolerance and, 42–43  
placebos and, 54–56  
responses to pain and, 43–44  
multiple sclerosis and, 602  
myofascial pain syndrome and, 569–570  
ongoing, 97*t*  
pain management and, 720–730  
physiologic responses, 43–45, 95*t*  
postmastectomy pain and, 604  
postthoracotomy pain and, 606  
of procedural pain, 366–367  
spinal cord injury and, 607  
tools for, 58–89  
breakthrough pain and, 75, 78  
communication strategies and, 84, 86, 89  
flow sheets and, 78–84, 85  
initial, 59–62, 60–61*f*, 60–61*t*  
neuropathic pain scale, 75, 76–77  
nursing admission, 58–59  
pain rating scales and, 62–75  
teaching to use, 67–75, 74*t*
- Association for Applied Psychophysiology and Biofeedback, 517
- ATC dosing, 175  
cognitively impaired elderly and, 704  
rescue dose and, 244–246
- Atenolol, migraine and, 555*t*
- Atherosclerosis, 696
- Ativan; *see* Lorazepam
- Atraumatic suturing, 395
- Atrophic stage of reflex sympathetic dystrophy, 582
- Audit, medical record pain management, 727
- Auditory disturbance in alcohol withdrawal, 457
- Aura, migraine, 552
- Aventyl; *see* Nortriptyline
- B
- Back pain, 599–600  
alternative treatment for, 690*t*  
angiography causing, 391  
arachnoiditis and, 596  
chronic, 473–474  
failed back syndrome and, 496  
osteoporosis causing, 573  
pregnancy causing, 615–616

- Back pain—cont'd  
 psychiatric setting and, 475–476
- Background pain with burn injury, 529*t*
- Baclofen, 305*t*  
 indications and dosages of, 343*t*  
 modulation of pain and, 23  
 multiple sclerosis and, 603  
 overview of, 324
- Bacteriostatic saline, 370
- Balanced analgesia  
 characteristics of, 174–175  
 clinical application of, 120, 120*t*  
 concept of, 174–175  
 definition of, 162  
 explanation of, 119–121  
 perioperative, 144–145
- Barbiturate for procedural analgesia, 381, 386
- Barriers  
 to assessment, 37*t*  
 to drug treatment, 449  
 to pain management improvement, 714  
 questionnaire, 93*t*  
 to treatment, 37*t*
- Barriers Questionnaire, 89, 92, 93
- Bathing, contrast, 411
- Bayer Select Aspirin-Free Headache, 149*t*
- BC preparation, 149*t*
- Beck Depression Inventory, 519
- Bedrest, osteoporosis and, 574
- Behaviors  
 addictive; *see* Addiction  
 drug-seeking, 52–53*t*, 429  
 addiction versus, 434–435  
 elderly and, 686–687  
 indicative of pain, 95*t*  
 memory of pain and, 30  
 pain  
 description of, 95  
 expectations about, 44–46  
 impaired communication and, 95, 98  
 in infant, 633–634, 633*t*, 649
- Behavioral method of treatment  
 drug abuse and, 442*t*, 445–446  
 infant and, 658–659  
 for procedural pain management, 389–390
- Benzocaine  
 for procedural pain, 369*t*  
 topical, 371–372
- Benzodiazepines  
 addiction to, 433  
 as adjuvant analgesic, 335  
 adverse effects of, 381  
 alcohol withdrawal and, 458  
 common, 495*t*  
 detoxification protocol, 458*t*  
 elderly and, 698  
 examples of, 327*t*  
 infant and, 655  
 equisdating doses, 656*t*  
 labor and delivery and, 618–619
- Benzodiazepines—cont'd  
 as nonanalgesic, 113  
 opioid with, 499  
 pregnancy and, 615  
 procedural analgesia with, 380, 381  
 misconceptions about, 364*t*  
 for procedural sedation, 385–386*t*
- Beta-blocker for migraine, 555*t*, 556
- Bethanechol  
 elderly and, 697  
 side effects of, 308
- Bier block, 584
- Biliary spasm, opioids causing, 265
- Bill of rights for patients with pain, 13
- Binding  
 opioid receptor sites and, 108  
 protein, in elderly, 688
- Bioavailability  
 definition of, 162  
 intraspinal anesthesia and, 220–222  
 of opioids, 167–169
- Biphosphonate, 325, 325*t*
- Bipolar disorder, 436
- Birth; *see* Labor and delivery
- Black market for drugs, 438–439
- Bleeding  
 angiography and, 391  
 nonsteroidal antiinflammatory drugs causing, 138, 144  
 gastrointestinal, 136, 137, 145–146  
 at operative site, 145–146  
 perioperative, 145–146
- Bleeding time  
 aspirin and, 135, 137  
 nonsteroidal antiinflammatory drugs and, 138, 145
- Block  
 nerve; *see* Nerve block  
 paravertebral sympathetic ganglion, 583–584
- Blood disorder  
 hemophilia and, 598–599  
 sickle cell disease, 585–588
- Blood  
 -brain barrier, 162  
 patch, 232  
 vessels, in migraine, 553
- Board, state medical, 9–10
- Board of Registered Nursing, 6
- Body surface area in burn injury, 527
- Boluses, 211  
 cesarean section and, 622–623  
 elderly and, 693  
 intraspinal, 220, 221  
 intermittent, 221*t*  
 titration of dose and, 247
- Bones  
 aseptic necrosis of, 539  
 cancer-related pain in, 109*t*, 113, 324–326, 325*t*, 533*t*  
 indomethacin affecting formation of, 147  
 malignant, 325*t*  
 osteoporosis and, 572–576
- Bowel obstruction, 326–327, 327*t*

- Brace for osteoporosis, 575
- Brachial plexus  
cancer-related pain and, 535*t*  
radiation fibrosis of, 540*t*
- Brain  
addiction and, 432  
dopamine pathway in, 434  
migraine and, 553  
opioid receptors in, 165–166  
pain perception and, 22
- Brand names of nonopioid drugs, 138*t*
- Braxton Hicks contraction, 616
- Breakthrough pain  
burn injury causing, 529*t*  
fentanyl for, 202–203  
opioids for, 175  
rating scale for, 75, 78  
selection of analgesic for, 121
- Breast  
postmastectomy pain and, 604  
postpartum pain and, 622
- Breast cancer, 532*t*  
age and, 678*t*
- Breast feeding, 610, 623–624  
acetaminophen during, 623  
adjuvant analgesics during, 623–624  
nonsteroidal antiinflammatory drugs during, 142  
opioid analgesics during, 623
- Breathing technique  
labor and delivery and, 617  
for relaxation, 419–420
- Brief Pain Inventory, 61, 62  
cultural differences and, 98
- Bromo-Seltzer, 148*t*
- Brompton's cocktail, 316
- Buccal administration of opioids, 195*t*, 201
- Buffered aspirin, 149  
gastric injury and, 137
- Bupivacaine  
breast feeding and, 623  
dosage of, 369*t*  
elderly and, 694  
injectable, 368  
intraspinal, 228  
labor and delivery and, 618, 620  
for procedural pain, 369*t*
- Buprenorphine  
characteristics of, 188  
equianalgesic doses of, 242*t*  
labor and delivery and, 112, 618  
opioid receptor sites and, 166
- Bupropion, 306*t*
- Burns  
depth of, 528*f*  
management pathway of acute care, 529*t*  
pain, 527–531, 528*f*
- Bursitis, 690*t*
- Butorphanol  
characteristics of, 188–189  
labor and delivery and, 618
- Butorphanol nasal spray, 112
- Bypass surgery, coronary artery, 694
- C
- Cafegot; *see* Ergotamine
- Caffeine  
as adjuvant analgesic, 315–316  
beverages containing, 151*t*  
breast feeding and, 624  
indications and dosages of, 344  
nonsteroidal antiinflammatory drugs with, 149–150, 149*t*
- CAGE questionnaire, 705
- Calan; *see* Verapamil
- Calcitonin  
bone pain and, 325, 325*t*  
indications and dosages of, 344  
neuropathic pain and, 321*t*, 330  
osteoporosis and, 574
- Calcium-channel blocker  
cluster headache and, 556*t*  
migraine and, 555*t*
- Cancer pain initiatives, 11
- Cancer-related pain, 531–543, 532*t*, 533*t*  
adjuvant analgesics for, 109*t*, 113  
bone pain and, 324–326, 325*t*  
bowel obstruction and, 326–327, 327*t*
- Brompton's cocktail for, 316  
characteristics of, 532–537  
cost of, 4  
death statistics, 532*t*  
description of, 531–532  
elderly and, 678–679, 678*t*  
family's attitude toward, 10  
intraspinal sufentanil for, 227  
intravenous opioid for, 211  
management of, 539–542  
mucositis and, 601–602  
musculoskeletal tumor, 533*t*  
neuropathic, 535–536*t*  
noncancer pain versus, 47–48  
nondrug treatment of, 401, 405  
oxycodone for, 243  
patient-controlled analgesia for, 249  
postchemotherapy, 538–539*t*  
postradiation, 540*t*  
postsurgical, 537*t*  
procedures and treatment causing, 537–540, 537–540*t*  
rescue analgesia for, 247–248  
resources for, 542  
sites of, 532*t*  
spinal cord compression as, 339–340  
stomal administration of opioid in, 205–206  
viscera involvement, 534*t*  
WHO analgesic ladder for, 115–119
- Cannabinoid, 334
- Capaisin, 305*t*  
adverse effects of, 332
- Carbamazepine, 305*t*  
adverse effects of, 322–323  
for child, 341*t*

- Carbamazepine—cont'd  
 indications and dosages of, 342*t*  
 neuropathic pain and, 321*t*  
 overview of, 321
- Carcinoma; *see* Cancer-related pain
- Cardiac disease in elderly, 698
- Cardiac surgery  
 in elderly, 678*t*  
 in infant, 662
- Cardiotoxicity of antidepressants, 309–310
- Cardiovascular system  
 antidepressants in elderly and, 697  
 Ehlers-Danlos syndrome and, 543  
 harmful effects of pain on, 25–26  
 local anesthetic in elderly and, 698
- Caregivers  
 for elderly, 684, 685*t*, 686  
 report of patient's pain, 39–40
- Carisoprodol, 305*t*, 327, 328  
 elderly and, 700  
 musculoskeletal pain and, 327*t*
- Case report, 302
- Catabolism, 16
- Catheters  
 in child, 237  
 epidural, 218*f*, 221*t*  
   location of, 248  
   patient education about, 366  
   removal of, 82, 236*t*  
 patient placement, 218*f*  
 spinal, 214–216, 232–233  
   intraspinal displacement and migration, 233*t*  
 urethral, 372
- Catheritization, atraumatic urethral, 372*t*
- Causalgia, 581–584
- Cause and effect diagram, 722*f*–723*f*
- Ceftriaxone with lidocaine, 371
- Ceiling analgesia, 104, 162  
 for acetaminophen, 141  
 definition of, 130  
 elderly and, 690  
 for opioid-nonopioid combination drugs, 134
- Celiac plexus neurolytic block for pancreatitis, 581
- Cell, natural killer, 29
- Central nervous system; *see also* Brain; Neurologic disorder  
 nonsteroidal antiinflammatory drugs affecting, 138  
 opioid receptors in, 165–166  
 opioid withdrawal in infant and, 632
- Centrally generated pain  
 classification of, 19*t*  
 definition of, 16
- Cerebrospinal fluid  
 dural puncture and, 232  
 intraspinal anesthesia and, 214, 221–222
- Certification of pain specialists, 11–12
- Cervical trigger point, 571*f*
- Cervical vertebral tumor, 533*t*, 536*t*
- Cesarean section, 621  
 clonidine for, 336  
 pain after, 622–623
- Cessation of opioid therapy, 270–271
- Cetacaine, 371–372
- Chart  
 equianalgesic, for opioids, 174, 240–243  
 graphic vital sign, 735
- Checklist, patient teaching, 273
- Chemical dependence, 429
- Chemical irritation, wound pain and, 592–593
- Chemotherapy, 538*t*–539*t*
- Chest surgery  
 in elderly, 678*t*  
 pain of, 605–606
- Chest trauma, 26
- Chest wall tumor, 533*t*
- Child  
 adjuvant analgesics for, 340  
   clonidine for, 336  
   dosage of, 341*t*  
 aspirin avoided in, 143*t*  
 bupivacaine for, 237–238, 368  
 cancer-related pain in, 537  
 conscious sedation in, 382–385*t*  
 epidural analgesia in, 236–239  
 local anesthetic toxicity in, 368  
 nondrug pain treatment for, 421, 422  
 nonsteroidal antiinflammatory drug for,  
   142–144, 143*t*  
 opioid for  
   intravenous, 211, 213  
   rectal administration of, 205  
 pain behavior in, 46  
 patient-controlled analgesia in, 253, 255*t*  
 rectal administration in, 150*t*  
 refrigerant spray for, 377  
 topical anesthetic for, 372
- Childbirth, 617–623; *see also* Labor and delivery
- Chloral hydrate  
 infant and, 655  
 procedural analgesia with, 386
- Chlordiazepoxide, 698, 699*t*
- Chloroform in topical agent, 332
- Chlorpromazine  
 for migraine, 554*t*  
 procedural analgesia with, 380
- Chlorzoxazone, 305*t*, 700  
 musculoskeletal pain and, 327*t*
- Chocolate, caffeine in, 150
- Choline magnesium trisalicylate  
 bleeding disorder and, 138, 144  
 dosage of, 139*t*  
   for child, 143*t*  
 patient information sheet on, 155–156
- Choline salicylate  
 dosage of, 139*t*  
   equianalgesic, 133*t*  
   opioid equivalent, 133*t*  
 trade name of, 138*t*
- Chronic fatigue immune deficiency syndrome, 597
- Chronic fatigue syndrome, 597
- Chronic illness problem inventory, 519



- Chronic pain, 467–520, 490–505  
 acute care setting and, 473–475  
 acute pain versus, 493–494  
 addiction and, 461–462  
   treatment center for, 477  
 adjuvant analgesic for, 109*t*, 112–113  
 admission assessment and, 492–493  
 antidepressants for, 310  
 assessment of, 477–487  
 of bone, 109*t*, 113, 324–326, 325*t*, 533*t*  
 breakthrough, 175; *see also* Breakthrough pain  
 cancer-related; *see* Cancer-related pain  
 challenges of, 472–473  
 in child, 143*t*; *see also* Child  
 combination analgesics for, 116  
 cost of, 472  
 definition of, 17, 468, 471  
 drug management in, 494–499  
 education about, 494  
 elderly and, 679  
 in infant, 640  
 intraspinal administration and, 219*f*  
 long-term planning in, 505  
 management techniques for, 505, 510  
 misconceptions about, 469–470*t*, 471  
 nerve blocks for, 510–513  
 nonmalignant  
   activity changes, 509*f*  
   anesthesia nerve block, 511–512*t*  
   differential blocks, 510*t*  
   examples, 472*t*  
   medication, 489*t*  
   opioid therapy, 498*t*  
   patient assessment, 486*t*  
   patient care, 491*t*  
   patient daily plan, 506*t*  
   patient future plan, 507*t*  
   patient questionnaire, 478–485*t*  
   psychiatric disorders, 476*t*  
   return visit survey, 508*t*  
   severity of, 509*f*  
   treatment, 489*t*  
   treatment goals, 488*t*  
 nonsteroidal antiinflammatory drugs for, 133–134, 138, 140, 142  
 opioid analgesics for, 492  
   written agreements about, 753–754  
 osteoporosis and, 574–575  
 placebos and, 492  
 polypharmacy in, 304  
 prevalence of, 471–472  
 previous acute pain and, 30  
 psychiatric settings and, 475–477  
 psychosocial considerations in, 499–503  
 referral for treatment of, 513, 516–520  
 rehabilitation and, 487–490, 503, 505  
 respect for individual and, 491–492  
 selection of analgesic for, 121  
 suicide risk and, 487
- Cimetidine  
 elderly and, 699*t*
- Cimetidine—cont'd  
 nonsteroidal antiinflammatory drugs and, 131*t*  
 ulcer prevention and, 137
- Circumcision, 371, 636–639  
 EMLA for, 376  
 memory of pain in, 30
- City of Hope Medical Center, 4–5, 274
- Classic migraine, 552
- Clearance, drug  
 of intraspinal local anesthetics, 228  
 of opioid, 169–170
- Clinical pathway, 679–680, 738–739
- Clinical practice guideline, 5, 7*t*
- Clinical scoring system for pain in infant, 641
- Clinical trial, types of, 302
- Clinician; *see* Health care professional
- Clodronate, 325
- Clomipramine, 305*t*, 306*t*  
 as adjuvant analgesic, 307  
 indications and dosages of, 343*t*
- Clonazepam, 305*t*  
 adverse effects of, 323  
 characteristics of, 335  
 indications and dosages of, 342*t*  
 as muscle relaxant, 327, 328  
 musculoskeletal pain and, 327*t*  
 neuropathic pain and, 321*t*  
 overview of, 322
- Clonidine, 305*t*  
 for crescendo pain, 336  
 dosage of, 314, 342*t*  
 epidural, 229, 231, 315*t*  
 herpes zoster and, 562  
 indications for, 314, 342*t*  
 intraspinal, 229, 231  
 mechanism of, 313–314  
 neuropathic pain and, 321*t*  
 peripheral neuropathy and, 579  
 for regional anesthesia, 337*t*
- Clorazepate, 698
- Cluster headache, 558–559, 558*f*  
 drugs for, 555*t*–556
- Coagulation, 598–599  
 nonsteroidal antiinflammatory drugs and, 135; *see also*  
 Bleeding  
 vascular surgery and, 25–26
- Cocaine  
 addiction to, 432*t*, 433  
 as adjuvant analgesic, 316  
 in topical mixtures, 373
- Cocktail, Brompton's, 316
- Codeine  
 characteristics of, 179*t*, 181  
 in combination drug, 117, 134  
 equianalgesic dosage of, 133*t*, 241*t*  
 infant and, 655  
 nebulized, 203  
 pregnancy and, 614  
 transdermal fentanyl and, 209*t*
- Coerced drug treatment, 446

- Cognitive impairment  
 effects of pain and, 28–29  
 elderly and, 675, 686–687, 701–705  
 nonsteroidal antiinflammatory drugs and, 135  
 pain assessment and, 94
- Cognitive-behavioral intervention  
 cancer-related pain and, 541  
 chronic pain and, 500–501  
 drug abuse and, 442*t*, 445–446  
 procedural pain management and, 389–390
- Cold, 406–411, 409*f*  
 arthritis and, 526  
 herpes zoster and, 562  
 injection site pain and, 394–395  
 pain reduction with, 390  
 patient and, 410*t*, 411*t*
- Colon cancer, 532*t*  
 age and, 678*t*
- Combination analgesics  
 brands and dosages, 149*t*  
 chronic pain and, 496  
 epidural, 694  
 examples of, 116–117  
 ketamine and morphine, 338  
 labor and delivery and, 618  
 mild pain and, 191  
 misconceptions about, 105*t*  
 nonsteroidal antiinflammatory, 132, 149*t*  
 opioid and nonopioid, 134  
 prevention of NSAID-induced ulcers and, 137  
 procedural analgesia with, 380  
 rationale for, 109–110, 115  
 WHO analgesic ladder and, 115–119
- Combined spinal-epidural anesthesia, 231
- COMFORT Scale, 649, 650
- Commission on Accreditation of Rehabilitation Facilities, 517
- Committee, pain care, 713, 715–737; *see also* Pain care committee
- Committee on Pain of the American Society of Addiction Medicine, 461
- Communication  
 aids to, 128  
 chronic pain treatment and, 488, 490  
 impaired, 92, 94–95, 98–99  
 nurse-physician, 92*t*  
 pain assessment and, 84, 86, 89
- Companion animal for relaxation, 421
- Compazine; *see* Prochlorperazine
- Complex regional pain syndrome, 581–584
- Compliance  
 opioids and, 193–194  
 patient education for, 123, 124
- Compression, spinal cord  
 cancer-related, 539  
 corticosteroids for, 312, 313, 339–340
- Confusion  
 dementia versus, 704*t*  
 elderly and, 675, 701–705
- Conscious sedation, 382–385*t*
- Consent, informed, 365
- Constipation  
 burn injury and, 529*t*  
 elderly and, 695  
 antidepressants and, 697  
 opioids causing, 262*t*
- Containment of infant, 659
- Contemplation stage of drug treatment, 447*t*, 448
- Contingency-based drug therapy, 446
- Continuous dysesthesia, 302  
 adjuvant analgesics for, 317
- Continuous infusion, 244; *see also* Infusion  
 intraspinal, 220  
 in opioid naive patient, 250–251
- Continuous quality improvement, 713–715; *see also* Quality improvement)
- Contract  
 definition of, 751–752  
 for opioid use, 499
- Contraction  
 Braxton Hicks, 616  
 opioid affecting, 619  
 postpartum, 622
- Contrast bathing, 411
- Controlled study, 302
- Controlled-release formulation in rescue analgesia, 121
- Conversion chart, equianalgesic; *see* Equianalgesic dosage
- Cope, 149*t*
- Coping response, 404–405  
 addiction and, 438  
 chronic pain and, 501–503
- Coping Strategies Questionnaire, 519
- Cord, spinal; *see* Spinal cord
- Coronary artery bypass surgery, 694
- Corticosteroid  
 as adjuvant analgesic, 311–313  
 for bone pain, 325*t*, 326  
 breast feeding and, 624  
 cancer-related pain and, 538*t*, 541  
 cluster headache and, 556*t*  
 elderly and, 697–698  
 examples of, 305*t*  
 fibromyalgia and, 549  
 malignant bowel obstruction and, 327, 327*t*  
 migraine and, 555*t*  
 pregnancy and, 615  
 respiratory effects and, 26  
 transduction of pain and, 18
- Cost  
 of chronic pain, 471–472  
 of drug treatment, 441*f*  
 of nonsteroidal antiinflammatory drugs, 141  
 of opioids, 194  
 of unrelieved pain, 4
- Counterirritation, 390
- COX-1, 130
- COX-2, 130
- Cramping, fibromyalgia and, 547–548
- Cream, EMLA; *see* EMLA
- Creatinine clearance, 170*t*
- Crescendo pain, 335–340

- CRIES neonatal pain scale, 642, 644*t*, 650  
 Criminal model of addiction, 431, 438–439  
 Crisis, sickle cell, 585–588  
 Criterion, 712  
 Critically ill infant, 661  
 Crohn's and Colitis Foundation of America, 517  
 Crohn's disease, 597–598  
 Cross-tolerance of opioids, 172  
   methadone and, 185–186  
 Crying by infant  
   opioid withdrawal and, 632  
   pain and, 633, 633*f*  
 CSEA; *see* Combined spinal-epidural anesthesia  
 Cultural factors in pain assessment, 57, 98–99  
 Cumulation of opioid, 169–170  
 Curriculum guidelines for pain management, 5  
 Cushingoid appearance, 312  
 Cutaneous stimulation, 390, 405–412  
   heat and cold for, 406–411  
   sites for, 406*f*  
   vibration as, 411–412  
 Cyclandelate, 699*t*  
 Cyclobenzaprine, 305*t*  
   elderly and, 700  
   fibromyalgia and, 548  
   as muscle relaxant, 327, 328  
   musculoskeletal pain and, 327*t*  
 Cyclone for mucositis, 602  
 Cyclooxygenase, 132*f*  
   nonsteroidal antiinflammatory drugs and, 130  
 Cyclooxygenase inhibitor, 130, 132*f*
- D**  
 Dalgan; *see* Dezocine  
 Dalmane; *see* Flurazepam  
 Darvon; *see* Propoxyphene  
 Data  
   definition of, 712  
   pain management, 720–730  
   qualify improvement, 721*t*  
 Deafferentation pain, 19*t*, 302  
 Death, pain causing, 17  
 Debilitation, 675, 700–701  
 Decadron; *see* Dexamethasone  
 Deep breathing, 419–420  
 Delirium  
   definition of, 675  
   opioids causing, 263*t*  
   meperidine, 183–184  
 Delivery, drug; *see* Route of administration; specific route  
 Delta opioid receptor site, 166  
 Delta-9-tetrahydrocannabinol, 334  
 Deltoid injection site, 394*f*  
 Deltoid trigger point, 571*f*  
 Dementia, 687  
   aging and, 702  
   confusion versus, 704*t*  
   definition of, 675  
 Demerol; *see* Meperidine  
 Depakene; *see* Valproic acid  
 Depakote; *see* Divalproex; Valproic acid  
 Dependence  
   addiction versus, 434  
   definition of, 50, 162, 429  
   HIV and, 567  
   in infant, 631  
   psychologic, 50, 173–174  
   substance, 429  
 Depolarization  
   definition of, 16  
   transduction of pain and, 18  
 Depression  
   alcohol addiction and, 436  
   as cause of pain, 48–49  
   chronic pain and, 499  
   definition of, 468  
   respiratory; *see* Respiratory depression  
 Dermal anesthesia, iontophoresis for, 377–378  
 Dermatomes, 217*f*  
   definition of, 363  
   herpes zoster and, 562  
   intraspinal anesthesia and, 221–222  
 Desipramine, 305*t*, 306*t*  
   as adjuvant analgesic, 307  
   breast feeding and, 623–624  
   for child, 341*t*  
   dosage of, 343*t*  
   indications for, 310, 343*t*  
   patient education about, 346–347*t*  
 Desyrel; *see* Trazodone  
 Determination stage of drug treatment, 448  
 Detoxification, 441–442  
   alcohol, 458  
   opioid, 459*t*  
   protocols, 456*t*, 458*t*, 459*t*  
 Dexamethasone, 305*t*  
   cluster headache and, 556*t*  
   high- and low-dose, 313  
   indications and dosages of, 343*t*  
   migraine and, 555*t*  
   spinal cord compression and, 339–340  
 Dexedrine; *see* Dextroamphetamine  
 Dexmedetomidine, 305*t*  
 Dextroamphetamine, 305*t*  
   as adjuvant analgesic, 314–315  
   for child, 341*t*  
   indications and dosages of, 344  
   morphine with, 339  
 Dextromethorphan, 305*t*  
   neuropathic pain and, 321*t*, 328–330  
 Dezocine  
   characteristics of, 189  
   equianalgesic doses of, 242*t*  
 DHE, migraine and, 554*t*  
*Diagnostic and Statistical Manual of Mental Disorders*  
   drug dependence and, 435  
   psychogenic pain and, 49  
   substance abuse and, 435  
 Diarrhea in HIV infection, 567

- Diary
  - headache, 551
  - pain relief, 200
- Diatheses, bleeding, 138
- Diazepam
  - elderly and, 698, 699*t*, 700
  - equisedating doses of, 656*t*
  - morphine with, 335
  - as muscle relaxant, 327, 328
  - musculoskeletal pain and, 327*t*
  - opioid with, 499
  - pregnancy and, 615
  - procedural analgesia and, 381, 385*t*
- Diclofenac
  - cost of, 141, 142
  - dosage of, 139*t*
  - perioperative, 145–146
- Diet in Crohn's disease, 598
- Diflunisal
  - antipyretic effect of, 144
  - cost of, 141, 142
  - dosage of, 139*t*
- Dihydroergotamine
  - cluster headache and, 555*t*
  - medication withdrawal and, 559
  - migraine and, 554*t*
- Dilantin; *see* Phenytoin
- Dilaudid; *see* Hydromorphone
- Diphenhydramine, 695
- Diphosphonate, 325; *see also* Biphosphonate
- Diprivan; *see* Propofol
- Discharge from hospital
  - chronic pain and, 505
  - subcutaneous continuous infusion and, 212
- Discomfort, reducing, 390*t*
- Disease model of addiction, 431–432
- Displacement, catheter, 233
- Distraction, 412–417
  - benefits and limitations, 413*t*
  - for brief pain episodes, 414*t*
  - indications for, 413–414
  - labor and delivery and, 617
  - music for, 415*t*
  - picture descriptions for, 417*t*
  - procedural pain management and, 389–390
  - sing and tap rhythm for, 415*t*
  - strategies for, 414–417
- Distress, reducing, 390*t*
- Distress Scale for Ventilated Newborn Infants (DSVNI), 645–647, 646*t*, 650
  - new scoring system, 647*t*
- Distribution of drug in elderly, 687, 688
- Divalproex, 305*t*
  - indications and dosages of, 342*t*
- Documentation
  - of infusion, 78–82
  - opioid and, 272
  - for outpatient, 82, 84
- Dolobid; *see* Diflunisal
- Dolophine; *see* Methadone
- Dopamine pathway, 434*f*
- Dopamine receptor, 333
- Dorsal column stimulation, 584
- Dorsogluteal injection site, 393*f*
- Dosage
  - for anticonvulsant, 324
  - of antidepressant, 310–311
  - ATC dosing and, 175
  - ceiling; *see* Ceiling analgesia
  - for elderly, 695
  - epidural analgesia in child and, 238
  - equianalgesic
    - for infant, 655
    - for nonopioids, 133*t*
    - for opioids, 174, 240–243
    - phenobarbital and, 458
  - of local anesthetic, 320
  - of nonsteroidal antiinflammatory drugs
    - adverse effects and, 147–148
    - examples of, 139*t*
  - nurse-activated dosing and, 177
  - opioid
    - in opioid-naïve patient, 250, 252*t*
    - rectal, 204–205
    - starting, 240–246
    - tolerance and, 171–173
  - patient-controlled analgesia and, 175–177; *see also* Patient-controlled analgesia
  - phenobarbital withdrawal equivalents, 458
  - PRN dosing and, 175
  - rescue dose and, 244–246
  - switching opioids and, 257
  - titration of; *see* Titration of dose
- Double blind study, 302
- Doxepin, 305*t*, 306*t*
  - as adjuvant analgesic, 307
  - indications and dosages of, 343*t*
  - tension headache and, 555*t*
- D-Penicillamine, arthritis and, 526
- DPT for procedural analgesia, 380
- Dressing
  - epidural analgesia in child and, 237
  - wound, 593–594
- Drug Enforcement Agency, 431
- Drug tolerance, addiction versus, 433–434
- Drug-receptor interaction, 165–166, 165*f*, 166*t*, 167*t*
  - absorption, 168*f*
- Drugs
  - addictive classes, 432*t*
  - effects of abuse, 433*t*
- Drug-seeking behavior, 50–52, 429
  - addiction versus, 434–435
- Drug treatment
  - major models, 442*t*
  - twelve steps, 433*t*
- Dry mouth, 308–309
- DSM-IV, 36
- DSVNI; *see* Distress Scale for Ventilated Newborn Infants
- Duraclon; *see* Clonidine
- Duragesic; *see* Fentanyl

- Dural puncture, 232
- Dyclone; *see* Dyclonine hydrochloride
- Dyclonine hydrochloride, topical, 372
- Dysesthesias
- continuous, 302, 317*t*
  - elderly and, 698
  - lancinating, 321*t*
  - paroxysmal, 321*t*
- Dysesthetic pain syndrome, 606
- Dyspnea, nebulized opioid and, 203
- Dystocia, 609
- Dystrophy, reflex sympathetic, 581–584, 582*f*
- E
- Education, patient
- acetaminophen and, 152
  - about adjuvant analgesics, 346–353
    - desipramine and, 346–347
    - gabapentin and, 350–351
    - mexiletine and, 352–353
    - nortriptyline and, 348–349
  - cancer-related pain and, 541
  - chronic pain and, 494, 504, 506–507
  - cold and heat and, 410
  - materials, 274*t*
  - for “new” pain relievers, 345
  - nondrug treatment and, 405
  - nonsteroidal antiinflammatory drugs and, 152
    - about opioid analgesic, 272–292
      - addiction and, 275–276
      - checklist for, 273
      - fentanyl patch and, 277–278
      - hydromorphone and, 279–280
      - morphine and, 281–286
      - oxycodone and, 287–290
      - patient-controlled, 291–292
      - resources for, 274
    - pain care committee’s role in, 737
    - pain management guidelines and, 123, 125, 126–127
    - pain rating scales and, 67*f*, 74
    - procedural pain management and, 365–366
    - resource materials, 274*t*
    - subcutaneous continuous infusion and, 212
- Education, professional
- lack of, 4–5
  - need for, 10
  - pain care committee and, 730, 734, 736–737
  - resources for, 6–8*t*
- Efficacy
- definition of, 162
  - of opioid, 170–171
- Ehlers-Danlos syndrome, 543–545
- distribution of chronic pain, 544*f*
- Elavil; *see* Amitriptyline
- Elderly patients, 674–706
- abuse of, 706
  - acute pain in, 677–678
  - adjuvant analgesics for, 695–698
  - age classifications for, 677
    - over age 100, 677*f*
- Elderly patients—cont’d
- alcohol abuse in, 705–706
  - assessment of, 686–687
  - cancer-related pain in, 678–679
    - caregiver role, 685*t*
    - probability of invasive, 678*t*
  - care settings for, 679–686
  - chronic nonmalignant pain in, 679
  - confusion, 704*t*
  - cognitive impairment in, 701–705
  - frail and debilitated, 700–701
  - inappropriate medication use in, 692–693, 699–700, 699*t*
  - mental state of, 703*t*
  - memory impairment in, 705
  - misconceptions about, 675–676*t*
  - nondrug pain treatment in, 700
  - nonmalignant conditions, 679*t*
  - nonopioid analgesics for, 689–691
  - nonsteroidal antiinflammatory drugs in
    - adverse effects of, 689*t*
    - alternative approaches, 690*t*
    - central nervous system effects, 138
    - dosages, 142
    - ketorolac, 146
    - long-term use, 689*t*
  - opioid analgesics for, 691–695
  - physical abuse of, 706
  - physiologic changes in, 687–689
  - polypharmacy in, 698–699
  - resources for, 684–685*t*
  - shingles and, 561–562
  - surgery types, 678*t*
- Electric stimulator for multiple sclerosis, 603
- Electromyography for peripheral neuropathy, 577
- Elimination of drug in elderly, 687, 688–689
- Emergency department
- cancer patient and, 542
  - chronic pain and, 473–474
  - Ehlers-Danlos syndrome and, 545
  - frequent use of, 51, 52, 53
  - nondrug pain treatment and, 423
  - sickle cell disease and, 587
- Emergency treatment of respiratory depression in infant, 655
- EMLA, 305*t*
- as adjuvant analgesic, 331
  - adverse effects of, 332
  - characteristics of, 373–377
  - circumcision and, 637
  - guidelines for, 375*t*
  - for infant, 656–657, 664–665
  - lidocaine, 375*t*
  - prilocaine, 375*t*
  - for procedural pain, 369*t*
- Empathy in drug treatment, 449
- Endocrine effects of pain, 23–25
- Endogenous opioid
- composition and function of, 165
  - definition of, 16
  - modulation of pain and, 22–23
- Endorphin, 17*t*, 164*t*

- End-stage renal disease, 135–136
- Enkephalin
  - misconceptions about, 17*t*, 164*t*
  - modulation of pain and, 22–23
- Enteric-coated aspirin, 149
  - gastric injury and, 137
- Enterocolitis, necrotizing, 660
- Enzyme
  - metabolites and, 169
  - nonsteroidal antiinflammatory drugs and, 130
- Epidural analgesia, 213–239
  - benefits of, 4
  - bioavailability and, 220–222
  - breast feeding and, 623
  - cancer-related pain and, 541
  - catheter for, 218*f*
    - documentation about, 82
    - location of, 248
    - removal of, 236
  - cesarean section and, 622–623
  - characteristics of drugs for, 195*t*
  - in child, 236–239
  - clonidine for, 229, 231, 315, 336, 337*t*
  - cognitive function and, 29
  - combined, 231
  - complications of, 232–236
  - drug delivery and, 214–220
  - effectiveness of, 25
  - elderly and, 694
    - cognitive impairment and, 701–702
  - fentanyl and, 225
  - gastrointestinal function and, 27–28
  - guidelines for, 215
  - hydromorphone and, 225–227
  - hypercoagulability and, 25–26
  - immune system and, 29
  - ketamine for, 338
  - labor and delivery and, 620
  - local anesthetics and, 227–229
    - muscle protein synthesis and, 25
  - methadone and, 227
  - misconceptions about, 214*t*
  - morphine and, 222, 224–225
  - in opioid-tolerant patient, 260–261
  - pancreatitis and, 581
  - patient education about, 366
  - patient selection for, 215
  - patient-controlled; *see* Patient-controlled analgesia
  - pediatric dosage and care, 238*t*
  - preemptive, 120–121
  - respiratory effects and, 26
  - side effect reduction, 254–255*t*
  - spinal anatomy and, 213–214
  - switching to intravenous analgesia from, 257–258
  - unwanted effects of, 230–231
- Epidural spinal cord compression, 539
- Epinephrine
  - local anesthetic toxicity and, 368
  - modulation of pain and, 23
  - in topical mixtures, 373, 374*t*
- Episiotomy pain, 622
- Equanil; *see* Meprobamate
- Equianalgesic dosage
  - for infant, 655
  - for nonopioids, 133*t*
  - for opioids, 174, 240–243, 241–243*t*
  - phenobarbital and, 458
- Ergotamine
  - cluster headache and, 555*t*
  - migraine and, 553, 554*t*
  - withdrawal from, 559
- Esophageal ulcer in HIV infection, 567
- Estrogen replacement therapy, 575
- Ethanol as adjuvant analgesic, 334–335
- Ethical issues of placebo use, 55
- Etodolac
  - brand name of, 138
  - cost of, 141
  - dosage of, 140, 140*t*
  - renal effects of, 138
- ETOH, addiction to, 432
- Eutectic mixture of local anesthetics; *see* EMLA
- Excedrin Aspirin Free, 148*t*
- Excedrin Extra Strength, 149*t*
- Exercise
  - chronic pain and, 503, 505
  - fibromyalgia and, 549
  - osteoporosis and, 575
- Extrapyramidal effect of neuroleptics, 333
- Extremely-low-birth-weight infant, 627
- Extremity
  - arthritis pain and, 523–525, 524*f*, 525*t*
  - elderly and, 679*t*
  - reflex sympathetic dystrophy and, 581–584
- Eye
  - anesthesia for, 372–373
  - cluster headache and, 558
  - Ehlers-Danlos syndrome and, 543
  - surgery on, 678*t*
  - zoster ophthalmicus and, 562
- F
- Faces pain rating scale, 63, 64–65*f*, 67
  - cultural differences and, 98
- Facial Action Coding System, 641
- Facial expression of pain in infant, 633*f*, 634*f*
- Facial pain, temporomandibular, 588–592, 589*f*
- Facility, pain
  - classification of, 514
  - increased numbers of, 10–11
- Factitious disorder, 36
- Failed back syndrome, 496
- Family
  - addiction and, 275–276*t*, 438
  - as barrier to pain management, 10
  - elderly and, 684, 686
  - of infant, 668
  - information for, 126–127*t*
  - nondrug treatment and, 402
  - pain rating scales and, 67*f*, 74

- Family-controlled analgesia, 177
- Fatigue, chronic, 597
- Feedback in drug treatment, 449
- Felbamate, 322
  - adverse effects of, 323
- Feldene; *see* Piroxicam
- Femoral head, aseptic necrosis of, 539
- Fenamate, 139*t*
- Fenoprofen, 139*t*
- Fentanyl
  - absorption pathway, 207*f*
  - characteristics of, 181–182
  - dosage, 209*t*
  - elderly and, 691
    - cognitively impaired, 702
  - equianalgesic doses of, 241*t*
  - infant and, 654*t*, 655, 667
  - intraspinal, 222, 223, 225
  - labor and delivery and, 619
  - mental status and, 267
  - nebulized, 203
  - for opioid-naïve adult, 225*t*
  - oral transmucosal, 201–203, 202*f*, 207*f*, 209*t*
    - for procedural pain, 378, 379*t*
    - as rescue analgesic, 245, 245*t*
  - overdose of, 269
  - patient information about, 277–278
  - patient-controlled analgesia with
    - in child, 255*t*
    - in opioid naïve patient, 252*t*
  - preemptive analgesia with, 120–121
  - pregnancy and, 614
  - procedural analgesia with, 379*t*
  - rib fracture and, 26
  - solubility of, 169
  - switching from, 257–258
    - to morphine, 208*t*
  - transdermal, 206–209, 207*f*
- Fetal heart rate, 621
- Fetus
  - drug effects on, 609–615
  - pain in, 635–636
- Fever in HIV infection, 567
- Fiber, nerve, 577
- Fibromyalgia, 545–550
  - alternative treatment for, 690*t*
  - assessment of, 548
  - classification criteria, 547*t*
  - description of, 545–547
  - pain management in, 547–549
  - tender points, 546*f*
- Fibrosis, radiation, 540*t*
- Fifth vital sign, 3, 731, 735*f*
- Fiorinal, tension headache and, 557
- First pass effect of opioids, 167
- Flare
  - of pain, in fibromyalgia, 547–548
  - of rheumatoid arthritis, 524–525
- Flecainide, 318
- Flexeril; *see* Cyclobenzaprine
- Flow sheet for pain management, 78–86
- Fluid therapy during labor and delivery, 621
- Flumazenil, 381
  - procedural analgesia with, 385*t*
- Fluoxetine, 305*t*
  - as adjuvant analgesic, 307
  - indications and dosage of, 343*t*
- Fluphenazine, 305*t*
- Flurazepam, 698, 699*t*
- Flurbiprofen, 139*t*
- FMS; *see* Fibromyalgia
- Food and Drug Administration pregnancy risk classifications, 609–610, 611
- Formulary analgesic reference guide, 737*t*
- Fox Chase Cancer Center, 274
- Fracture
  - osteoporosis and, 573*f*, 574
  - rib, fentanyl for, 26
- Frail elderly, 700–701
- “Frequent flyer,” 51, 52, 53
- Full agonist; *see* Mu agonist
- G
- GABA agonist; *see* Baclofen
- GABAergic drug, 305*t*
- Gabapentin, 305*t*
  - adverse effects of, 323
  - for child, 341*t*
  - dosage of, 324, 342*t*
  - elderly and, 697
  - indications for, 342*t*
  - neuropathic pain and, 321*t*
  - overview of, 322
  - patient education about, 350–351*t*
  - reflex sympathetic dystrophy and, 583
  - trial of, 324
- Gain, secondary, 41–42
- Gallium nitrate, 325
  - for bone pain, 325, 326
- Gamma-aminobutyric acid, 22–23
- Ganglion blockade, 583–584
- Gastrointestinal bleeding in elderly, 689–690
- Gastrointestinal disorder
  - corticosteroid and, 312, 698–699
  - Crohn’s disease and, 597–598
  - Ehlers-Danlos syndrome and, 543
  - elderly and, 679*t*, 689–690, 698–699
  - harmful effects of pain on, 27–28
  - malignant bowel obstruction and, 326–327
  - nonsteroidal antiinflammatory drugs and, 130, 135, 136–137
    - perioperative bleeding and, 145–146
  - opioid withdrawal in infant and, 632
  - opioids causing, 261, 262–263*t*
  - pancreatitis and, 579–581
- Gastrointestinal surgery in elderly, 678*t*
- Gastroprotective therapy, 137
- Gel pack, cold, 409*f*
- Gender
  - pain assessment and, 57
  - pain in infant and, 649–650

- General anesthesia, procedural, 386–389
- Generic name of nonopioid drugs, 138*t*
- Genetic disorder, sickle cell disease as, 585–588
- Genitourinary system, effects of pain on, 27
- Gingival administration of opioids, 201
- Glucocorticoid; *see* Corticosteroid
- Glucose-6-phosphate dehydrogenase deficiency, 376
- Glutamate in pain transmission, 22
- Gold salts for arthritis, 526
- Goody's Extra Strength, 149*t*
- Gout, 690*t*
- GR90291, 190
- Graphic rating scale, 62–63
- Graphic vital signs record, 735
- Gross motor movement in infant, 634
- Group drug therapy, 446
- Growth hormone, 24
- Guanethidine, 584
- H**
- Half-life
- definition of, 162
  - of opioid, 169–170
- Hallucination, opioids causing, 263*t*
- Hallucinogen, 432*t*, 433
- Haloperidol in elderly, 702
- Handheld vibrator, 411–412
- Harmful effects of pain, 3–4, 23–32, 24*t*
- H<sub>2</sub>-blocker, 131*t*
- ulcer prevention and, 137
- Head and neck pain
- elderly and, 679*t*
  - mucositis and, 601–602
  - myofascial, 571*f*
- Headache, 550–560
- alcohol withdrawal and, 457
  - assessment of, 550, 552
  - breast feeding and, 624
  - caffeine-containing analgesics and, 150
  - cluster, 555–556*t*, 557–559
  - description of, 550
  - diagnosis of, 552*f*, 557*f*, 558*f*
  - diary about, 551*t*
  - gel pack for, 409*f*
  - medications for, 554–556*t*
  - migraine, 552–556
    - in child, 143*t*
  - nonsteroidal antiinflammatory drugs for, 132
  - postdural puncture, 232
  - pregnancy and, 615
  - rebound, 559*t*
  - tension-type, 555*t*, 557–558
- Health care professional
- expectations about pain of, 44–46
  - infant and, 661–663, 668
  - nondrug treatment and, 402–403
  - nurse
    - certification of, 11, 13
    - expectations about pain of, 44
    - pain resource, 5
- Health care professional—cont'd
- nurse—cont'd
    - role of, 125, 128
    - undertreatment of pain and, 4–5, 9–10
- Heart
- antidepressant effects on, 309–310
  - elderly and, 698
- Heart surgery
- elderly and, 679*t*
  - in infant, 662
- Heartburn in pregnancy, 616
- Heat, 406–411
- arthritis and, 526
  - contrast bathing, 411*t*
  - fibromyalgia and, 549
  - patient use of, 410*t*
- Hematologic disorder, 135, 138
- perioperative, 145–146
- Hematoma, epidural, 234–236
- Hemodynamics
- clonidine and, 336
  - epidural local anesthetics and, 231
- Hemoglobin
- elderly and, 690
  - sickle cell disease and, 585
- Hemophilia, 598–599
- HIV infection in, 599
  - nonsteroidal antiinflammatory drugs and, 138, 144
- Hepatic impairment
- acetaminophen causing, 134–135, 151–152
  - tramadol and, 191
- Heroin, 432*t*
- addiction to, 9, 51, 53, 433
- Herpes zoster, 561–564
- chronic pain and, 31
  - elderly and, 696
- Hip replacement, 252
- Histamine blocker
- elderly and, 699
  - nonsteroidal antiinflammatory drugs and, 131*t*
  - ulcer prevention and, 137
- Histoacryl blue, 395
- History, analgesic, 123, 124
- HIV; *see* Human immunodeficiency virus
- peripheral neuropathy in, 576
- Home care
- for cancer patient, 542
  - Ehlers-Danlos syndrome and, 545
  - for elderly, 683–686
  - sickle cell disease and, 587
- Hormone
- osteoporosis and, 575
  - pain and, 24
- Hospice care, 681
- creation of, 10–11
- Hospice nurse certification, 13
- Hospitalization
- of elderly, 679–681
  - musculoskeletal effects of, 28
- 5HT<sub>1</sub> receptor, 553



- Human immunodeficiency virus (HIV) infection, 564–568  
 pain sources and locations, 566*f*  
 peripheral neuropathy and, 576
- Humoral head, aseptic necrosis of, 539
- Hurricane; *see* Benzocaine
- Hydrocodone, 116, 134  
 characteristics of, 179*t*, 182  
 in combination  
   fixed, 116–117  
   opioid–nonopioid, 134  
 equianalgesic dosage of, 133*t*, 240, 241*t*, 243  
 as fixed combination, 116–117  
 pregnancy and, 614
- Hydromorphone  
 as addictive drug, 432*t*  
 bioavailability of, 169  
 characteristics of, 179*t*, 182–183  
 elderly and, 691  
 equianalgesic doses of, 241*t*  
 intraspinal, 223, 225–226  
 mental status change and, 267  
 nebulized, 203  
 for opioid–naive adult, 225*t*, 252*t*  
 patient information about, 279–280  
 patient–controlled analgesia with, 252*t*, 265  
   cardiovascular effects of, 25  
   in child, 255*t*  
 sickle cell disease and, 587  
 solubility of, 169  
 transdermal fentanyl and, 209*t*
- Hydrophilic, 162
- Hyperalgesia, 429
- Hypercoagulation as stress response, 25
- Hypersensitivity, aspirin, 144
- Hypnosis for burn pain, 531
- Hypnotic  
 as addictive drug, 432*t*  
 elderly and, 699*t*
- Hypotension  
 antidepressants and, 308  
   in elderly, 697  
 labor and, 621
- Hypoxemia, in elderly, 701
- Hytrin; *see* Terazosin
- I
- Iatrogenic risk, 474
- Ibuprofen; *see* Ibuprofen
- Ibuprofen  
 caffeine with, 316  
 for child, 143*t*  
 in combination drugs, 134  
 dosage of, 139*t*, 143*t*  
 elderly and, 690  
 gastrointestinal side effects of, 136–137  
 overdose of, 152  
 patient information sheet for, 153–154*t*  
 tension headache and, 557–558
- Ibu-Tab; *see* Ibuprofen
- Ileus as stress response, 27–28
- Illegal drug, 438–439
- Illness Behavior Questionnaire, 519
- Imipramine, 305*t*, 306*t*  
 as adjuvant analgesic, 306–307  
 for child, 341*t*  
 indications and dosages of, 343*t*
- Imitrex, Sumatriptan
- Immune deficiency  
 chronic fatigue and, 597  
 fatigue and, 597  
 HIV infection and, 597
- Immune system effects of pain, 29–30
- Immunization, 638–639, 638*t*
- Immunocompetence, 29
- Implantation of electric stimulator, 603
- Incisional pain, 409*f*
- Indicator, 712
- Indinavir, 567
- Individualization of analgesic regimen, 121–123
- Indocin; *see* Indomethacin
- Indomethacin  
 bone formation and, 147  
 dosage of, 139*t*  
   pediatric, 143*t*, 654  
 elderly and, 699*t*
- Infants, 629–669  
 abstinence syndrome in, 609  
 anesthesia dosage, 657*t*  
 assessment of, 639–640, 649–651  
 circumcision in, 371, 636–637  
 consequences of pain in, 631–635  
 definition of pain in, 628  
 developmental care, 658*t*,  
 EMLA in, 376  
 infusion rates, 654*t*  
 measurement of, 640–649  
 memory of pain in, 30  
 misconceptions about, 627*t*, 628–631  
 opioid weaning flowsheet, 632*t*  
 operational definitions, 648*t*  
 pain during birth in, 635–636  
 pain management in  
   algorithm for, 662*f*–663*f*  
   CRIES measurement score, 646*t*  
   DSVNI, 646*t*, 647*t*  
   distress scale for ventilated facial expressions, 633*f*  
   guidelines, 664–667*t*  
   health care professional’s role in, 661–663, 668  
   immunizations, 638*t*  
   multidimensional assessment, 650*t*  
   multidimensional measures, 650*t*  
   minimizing, 661*t*  
   nonpharmacologic, 658–661  
   parents’ role in, 667  
   pharmacologic, 651–658, 656*t*, 657*t*  
   PIPP, 645*t*  
   protocol for, 664–667  
   unidimensional measures, 643*t*

- Infants—cont'd
- preterm, 609, 637–638
    - interventions, 662–663*t*
  - procedural pain in, 638–639
  - respiratory depression, 655*t*
  - silent cry, 634*f*
  - undertreatment of pain in, 628–631
- Infection
- human immunodeficiency virus, 564–568, 566*f*, 576
  - intraspinal analgesia and, 234, 235*t*
  - Lyme disease and, 600–601
  - masking of, 144
  - opportunistic, 567
  - varicella-zoster, 561–564, 561*f*
- Inflammation
- arachnoiditis and, 596
  - arthritis causing, 523–525, 524*f*, 525*t*
  - Crohn's disease and, 597–598
  - mucositis and, 601–602
  - pancreatic, 579–581
  - wound pain and, 592–593
- Inflammatory mediator, 130
- Information, patient/family, 126–127*t*
- Informed consent, 365
- Infusion
- flow sheet for, 78–82
  - intraspinal, 220; *see also* Intraspinal analgesia
  - lidocaine in, 339, 370–371
  - local anesthetic, 317, 320
  - needle placement, 211*f*
  - of neurotoxic agent, 233
  - opioid, 211
    - in opioid naive patient, 250–251
    - subcutaneous continuous, 211*t*, 212–213*t*
  - remifentanyl, 190
- Inhalation, nitrous oxide, 388–389
- Initial pain assessment, 59–62
- Injections
- fibromyalgia and, 549
  - intramuscular, technique for, 391, 392–395*f*, 394–395
  - local anesthetic, 368–371
  - low back pain and, 600
  - nerve block; *see* Nerve block
  - of neurotoxic agent, 233
  - osteoporosis and, 575
  - painful, 370–371
  - reducing discomfort, 392*t*
  - trigger point, 570
- Injury
- infant and, 638–639
  - needle or catheter, 233
  - spinal cord, 606–607
  - wound pain and, 592–595
- Innovar for labor and delivery, 618
- Inpatient
- drug treatment and, 454–456, 461*t*
  - Ehlers-Danlos syndrome and, 545
  - oral patient-controlled analgesia for, 199
  - sickle cell disease and, 587
- Institutional barriers to pain management, 713
- Institutional commitment to pain management, 715–738; *see also* Pain management
- Institutional needs assessment tool, 724–726
- Insulin, 24
- Intensity of pain
- initial assessment of, 59
  - opioid analgesic and, 191–192
- Interaction
- drug-receptor, 165–166, 165*f*, 166*t*, 167*t*
  - opioid, 192–193
- Intercostal nerve, 535*t*
- Interdisciplinary pain care committee, 713, 715–737; *see also* Pain care committee
- International Association for the Study of Pain, 5
- classifications of pain facilities, 514
  - clinical practice guidelines of, 7
  - education resources of, 6
  - founding of, 11
  - infants and, 628
  - malingered and, 41
- International Headache Society, 550, 552
- Internet resources, 745–750
- Interstitial Cystitis Association, 517
- Interviewing, motivational, 446–450
- Intestine, Crohn's disease of, 597–598
- Intolerance, aspirin, 144
- Intraarterial opioid administration, 196*t*
- Intracerebroventricular administration, 196*t*
- Intracranial pressure, corticosteroids for, 312
- Intractable migraine, 556
- Intractable pain treatment act, 9
- Intramuscular administration
- avoidance of, 121
  - inappropriate, 54
  - of opioid, 209–210
  - reducing pain of, 391–394
  - Z-track, 391, 392
- Intranasal administration, 195*t*, 203
- definition of, 162
  - effectiveness of, 25
  - midazolam and, 381
- Intraoral appliance for temporomandibular dysfunction, 590
- Intrapleural analgesia for pancreatitis, 581
- Intraspinal analgesia, 213–239; *see also* Epidural analgesia
- bioavailability and, 220–222
  - catheter removal and, 236
  - in child, 236–239
  - clonidine and, 229, 231
  - combined, 231
  - complications of, 232–236
  - drug delivery and, 214–220
  - for elderly, 693–694
  - fentanyl and, 225
  - guidelines for, 215
  - hydromorphone and, 225–227
  - labor and delivery and, 619–621
  - local anesthetics and, 227–229
  - methadone and, 227

- Intraspinal analgesia—cont'd  
 morphine and, 222, 224–225  
 spinal anatomy and, 213–214, 216–217*f*  
 use of, 215*t*
- Intrathecal administration, 196*t*, 213–239; *see also* Intraspinal analgesia  
 for labor and delivery, 619–620
- Intravenous administration; *see also* Infusion  
 lidocaine, 338–339  
 of opioid, 195*t*, 211, 213  
 cancer-related pain and, 541  
 methadone and, 186  
 oral analgesia after, 258–259  
 oxymorphone and, 187  
 for procedural pain, 378, 379*t*  
 needle placement, 211*f*  
 patient-controlled; *see* Patient-controlled analgesia  
 remifentanyl and, 190
- Invirase; *see* Saquinavir
- Involution of uterus, 609
- Ion, transduction of pain and, 18
- Iontophoresis, 377–378
- Irritation, gastrointestinal, 136
- Isometheptene, 554*t*
- Isoptin; *see* Verapamil
- Isoxsuprine, 699*t*
- J**
- Jaw pain, 588–592
- JCAHO; *see* Joint Commission on Accreditation of Health-care Organizations
- Joint  
 arthritis of, 523–525, 524*f*, 525*t*  
 elderly and, 679*t*  
 temporomandibular, 588–591
- Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 3, 730, 733
- Journals on pain management, 5, 8, 738
- K**
- Kangaroo care, 660
- Kappa opioid receptor site, 166
- Ketamine, 305*t*  
 for crescendo pain, 336–338  
 neuropathic pain and, 321*t*, 328–330  
 procedural analgesia with, 386–387, 387*t*
- Ketoprofen  
 dosage of, 139*t*  
 overdose of, 152
- Ketorolac  
 for acute pain, 132  
 adverse effects of, 146*t*, 147  
 for child, 143*t*, 144  
 dosage of, 139*t*, 143*t*  
 elderly and, 690–691  
 oral administration of, 145  
 parenteral administration of, 133, 144  
 in child, 144  
 perioperative use of, 146  
 for postoperative pain, 145
- Ketorolac—cont'd  
 preoperative use of, 133, 144  
 procedural analgesia with, 380–381  
 renal function and, 146–147  
 for surgical patient, 147  
 in terminally ill patient, 134
- Kidney damage from acetaminophen, 135–136
- Kindling effect, 433–434
- Klonopin; *see* Clonazepam
- Knee replacement, 694
- L**
- LAAM, 443–445
- Label  
 chronic pain and, 492
- Labeling  
 addiction as, 51–52
- Labor and delivery, 609–623  
 benzodiazepines in, 618–619  
 buprenorphine avoided in, 112  
 clonidine for, 336  
 controversies regarding, 621  
 epidural meperidine ion, 226  
 lidocaine for, 370  
 local anesthetics in, 618  
 nondrug methods during, 617–618  
 opioids in, 619  
 pain in infants during, 635–636  
 parenteral pain relief during, 619  
 patterns of labor pain, 617  
 postpartum pain and, 621–622  
 regional techniques during, 619–621
- Laceration, atraumatic suturing of, 395
- Lactation, 623–624  
 AAP classifications, 623*t*
- Ladder, WHO analgesic, 115–119, 117*f*  
 cancer-related pain and, 539, 541
- Lamotrigine, 305*t*, 322  
 adverse effects of, 323
- Lancinating pain, 302  
 adjuvant analgesics for, 109*t*, 320–324  
 anticonvulsants for, 697  
 herpes zoster and, 562
- Legal issues with placebo use, 55
- LET, 373, 374
- Levator scapulae trigger point, 571*f*
- Levo-alpha-acetylmethadol, 443–445
- Levo-Dromoran; *see* Levorphanol
- Levorphanol  
 characteristics of, 179*t*, 183  
 elderly and, 692  
 equianalgesic doses of, 241*t*
- Library, pain management, 738
- Lidocaine  
 buffered, 370, 371*t*  
 bupivacaine with, 368  
 burn injury and, 530–531  
 circumcision and, 636–637  
 cluster headache and, 559  
 elderly and, 698

- Lidocaine—cont'd  
 in EMLA; *see* EMLA  
 infant and, 656  
 injectable, 368–371  
 intraspinal, 228  
 labor and delivery and, 618  
 migraine and, 555*t*  
 neuropathic pain and, 318  
 parenteral, 338–339  
 for procedural pain, 369*t*  
 topical, 331–332, 372  
 in topical mixtures, 373, 374*t*, 375*t*
- Lifestyle in pain assessment, 58
- Ligament, round, 615
- Limb pain, phantom, 603–604
- Limbitrol; *see* Chlordiazepoxide
- Lioesal; *see* Baclofen
- Lipid solubility of opioids, 169
- Lipophilic, definition of, 162
- Lipophilic opioid  
 pregnancy and, 614  
 transmucosal, 201
- Listening, active, 416*f*
- Lithium for cluster headache, 556*t*
- Liver  
 acetaminophen and, 134–135, 151–152  
 opioid analgesia and, 192
- Local anesthetic; *see also* Lidocaine  
 as adjuvant analgesic, 316  
 adverse effects of, 318–319  
 for child, 239, 341*t*  
 elderly and, 694, 699*t*  
 epidural  
 in child, 239  
 muscle protein synthesis and, 25  
 unwanted effects of, 230–231, 230*t*  
 eutectic mixture of; *see* EMLA  
 examples of, 305*t*  
 gastrointestinal function and, 27  
 guidelines, 367*t*, 369–370*t*  
 indications and dosages of, 344  
 infant and, 656  
 intraspinal, 227–229  
 labor and delivery and, 618, 620  
 low back pain and, 600  
 mechanism of action of, 318  
 neuropathic pain and, 317–320  
 parenteral, 338–339  
 perioperative/postoperative, 145  
 pregnancy and, 614  
 procedural pain and, 367–378  
 guidelines for, 367*t*  
 injectable, 368, 370–371  
 iontophoresis and, 377–378  
 topical, 371–377  
 toxicity of, 368
- Location of pain, 59
- Lodine; *see* Etodolac
- Long-term care facility, 681–683  
 selection of, 682–683*t*
- Loracet, 134
- Lorazepam  
 burn injury and, 529*t*  
 equisedating doses of, 656*t*  
 infant and, 655  
 procedural analgesia and, 381, 385*t*
- Lortab; *see* Hydrocodone
- Low back pain, 599–600
- Low-birth-weight infant, 627
- LSD, addiction to, 433
- Ludiomil; *see* Maprotiline
- Lumbar epidural analgesia, 222  
 labor and delivery and, 620
- Lumbar plexus pain, cancer-related, 535*t*
- Lumbosacral plexus, radiation fibrosis of, 540*t*
- Lumbosacral vertebral tumor, 536*t*
- Lung cancer, 532*t*  
 age and, 678*t*
- Lyme disease, 600–601
- M
- Magnesium, migraine and, 553
- Magnesium salicylate  
 bleeding disorder and, 144  
 dosage of, 139*t*  
 opioid equivalent, 133*t*  
 nonprescription brands of, 151*t*
- Maintenance stage of drug treatment, 448
- Major histocompatibility complex in Crohn's disease, 597
- Malignancy, 531–543; *see also* Cancer-related pain
- Malignant bowel obstruction, 326–327, 327*t*
- Malingering, 36, 41
- Maprotiline, 305*t*, 306*t*, 307
- Marcaine; *see* Bupivacaine
- Marijuana addiction, 432*t*, 433
- Masking of infection, 144
- Massage, 420–421  
 fibromyalgia and, 549
- Mastectomy, 604
- Maternal hypotension in labor, 621
- Maternal-placental-fetal drug transfer, 610–611, 613*f*
- Maximally Discriminative Facial Coding System, 641
- Mayday Pain Resource Center, 6
- McGill Pain Questionnaire, 75, 577
- Measurement of pain in infant, 639–651, 643*t*, 650*t*
- Mechanical ventilation, weaning from, 271–272
- Meclofenamate, 139*t*
- Meclomen; *see* Meclofenamate
- Mediator, inflammatory, 130
- Medical model of addiction, 431–432
- Medical record pain management audit, 727
- Medication, patient information about, 277–292*t*
- Mefenamic acid, 139*t*
- Membrane potential, resting, 18
- Memory loss, 705
- Memory of pain in infant, 630–631
- Meningoencephalitis, 562
- Menopause, osteoporosis and, 575
- Mental disorder, psychogenic pain in, 48–50

- Mental status  
aging and, 702–704, 704*t*  
alcohol withdrawal and, 457  
Mini-Mental State examination and, 702, 703  
opioids causing change in, 263*t*, 266–267  
pain effects on, 28–29
- Mepergan, 618
- Meperidine  
breast feeding and, 623  
characteristics of, 179*t*, 183–185  
elderly and, 692–693  
equianalgesic dosages of, 133*t*, 241*t*  
intraspinal, 223, 226–227  
labor and delivery and, 618  
misconceptions about, 184*t*  
pancreatitis and, 581  
patient-controlled analgesia with, 252*t*  
pregnancy and, 614  
procedural analgesia with, 379*t*, 380  
sickle cell disease and, 587  
switching from, 255–256
- Mepivacaine, intraspinal, 228
- Meprobamate in elderly, 699*t*
- Mescaline addiction, 433
- Meta-analysis double blind study, 302
- Metabolic disorder  
fibromyalgia and, 547  
opioid withdrawal in infant and, 632
- Metabolic effects of pain, 23–25
- Metabolism in elderly, 687, 688
- Metabolite  
definition of, 162  
opioid, 169  
of morphine, 691  
pregnancy and, 614  
of remifentanyl, 190
- Methadone  
addiction and, 432*t*, 433, 443–445  
cancer-related pain and, 541  
characteristics of, 179*t*, 185–186  
elderly and, 692  
equianalgesic doses of, 242*t*  
intraspinal, 227  
morphine versus, 186  
oral administration of, 185, 185*t*  
pregnancy and, 614  
transmucosal of, 201
- Methemoglobinemia, EMLA and, 332, 376
- Methocarbamol, 305*t*  
elderly and, 700  
as muscle relaxant, 327, 328
- Methotrimeprazine, 305*t*  
dosage of, 334  
indications and dosages of, 344
- Methylphenidate, 305*t*  
as adjuvant analgesic, 314–315  
for child, 341*t*  
indications and dosages of, 344
- Methylprednisolone, 305*t*
- Methylsergide  
cluster headache and, 556*t*  
migraine and, 555*t*
- Metoclopramide  
mechanism of action of, 333  
migraine and, 554*t*  
rebound headache and, 559
- Mexiletine, 305*t*  
adverse effects of, 318–319  
for child, 341*t*  
elderly and, 698  
herpes zoster and, 562  
indications and dosages of, 344  
neuropathic pain and, 318, 321*t*  
patient education about, 352–353*t*  
peripheral neuropathy and, 579
- Mexitil; *see* Mexiletine
- M3G, 180–181, 181*t*
- M6G, 180–181, 181*t*
- Midazolam  
equisedating doses of, 656*t*  
infant and, 655  
morphine with, 335  
procedural analgesia and, 381, 385*t*
- Midrin, 554*t*
- Migraine headache, 552–556, 552*f*  
breast feeding and, 624  
in child, 143*t*
- Migration, catheter, 233
- Millon Clinical Multiaxial Inventory, 519
- Miltown; *see* Meprobamate
- Mini-mental state, 703
- Minipress; *see* Prazosin
- Minnesota Multiphasic Personality Inventory-2, 519
- Misoprostol  
elderly and, 690  
nonsteroidal antiinflammatory drugs and, 131*t*  
ulcer prevention and, 137
- Mitochondria in fibromyalgia, 547
- Modified Behavioral Pain Scale, 641
- Modulation of pain, 16, 19*t*  
antidepressants and, 309*f*  
definition of, 106*f*  
illustration of, 21, 107*f*, 319  
local anesthetics and, 319*f*  
process of, 22–23
- Monitoring  
of antidepressant therapy, 311  
by pain care committee, 733–734
- Monoamine oxidase inhibitor, 183
- Mononeuropathy, 19*t*
- Moral model of addiction, 431
- Morbidity, 16
- Morphine  
addiction to, 432*t*, 433  
benzodiazepines with, 335  
blood levels of, 181*t*  
buccal administration of, 201  
burn injury and, 529*t*, 530  
cancer-related pain and, 541

- Morphine—cont'd
- characteristics of, 179*t*, 180–181
  - dextroamphetamine with, 339
  - in elderly, 691
    - cognitively impaired, 701, 702
  - equianalgesic doses of, 241*t*
  - gastrointestinal function and, 27–28
  - immune system and, 29
  - infant and, 654–655, 654*t*, 666
  - intraspinal, 222–225
  - intravenous administration of, 211
  - ketamine with, 338
  - mental status change and, 267
  - metabolites of, 169
  - methadone versus, 186
  - nebulized, 203
  - for opioid-naïve adult, 225*t*
  - oral, 197–198
  - patient information about, 281–286*t*
  - patient-controlled analgesia with
    - in child, 255
    - in opioid naïve patient, 252*t*
    - postoperative, 250–251
  - pregnancy and, 614
  - procedural analgesia with, 379*t*
  - sickle cell disease and, 587
  - switching from, 256–257
  - transdermal fentanyl and, 208–209, 209*t*
  - transmucosal administration of, 201
- Morphine-3-glucuronide, 691
- Morphine-6-glucuronide, 691
- Morphine-like drug; *see* Mu agonist
- Mortality, 16
- Motivational approaches to drug treatment, 448–450
- Motivational interviewing, 446–450
- Motor deficit with epidural local anesthetics, 230*t*
- Motor vehicular accident by elderly, 698
- Motrin; *see* Ibuprofen
- Mouth
- mucositis and, 601–602
  - temporomandibular dysfunction and, 588–592
- Movement
- pain in infant and, 634
  - wound pain and, 593
- MPS, 548
- Mu agonist; *see also* Individual drug
- agonist-antagonist with, 112
  - characteristics of, 178–180, 180*t*
  - codeine, 181
  - combination analgesics with, 116
  - comparison of, 113–114
  - definition of, 104, 162
  - examples of, 109*t*
  - fentanyl, 181–182
  - hydrocodone, 182
  - hydromorphone, 182–183
  - levorphanol, 183
  - meperidine, 183–185
  - methadone, 185–186
  - morphine, 180–181
- Mu agonist—cont'd
- oxycodone, 186–187
  - oxymorphone, 187
  - propoxyphene, 187–188
  - titration of, 122
- Mu opioid receptor site, 166
- Mucosa, gastric, 136
- Mucositis, 601–602
- Multidimensional Pain Inventory, 519
- Multidimensional pain measure for infant, 642–649, 650, 651*t*
- Multidisciplinary pain care program for elderly, 680–681
- Multigravida, 609
- Multimodal, continuous analgesia; *see* Balanced analgesia
- Multiple sclerosis, 602–603
- charting example, 492*t*
- Muscle, temporomandibular dysfunction and, 588–592
- Muscle protein synthesis, 25
- Muscle relaxant
- elderly and, 700
  - examples of, 305*t*, 327
  - misconceptions about, 303*t*
  - osteoporosis and, 574
- Musculoskeletal system
- adjuvant analgesics for, 327*t*
  - Ehlers-Danlos syndrome and, 543–545
  - fibromyalgia and, 545–550
  - gel pack for injury to, 409*f*
  - harmful effects of pain on, 27–28
  - postpolio syndrome, 604–605
  - tumor of, 533*t*
- Music
- active listening, 416*f*
  - for distraction, 391*t*, 415, 416*f*
  - in procedural pain management, 390
  - for relaxation, 421
- Myelopathy, radiation, 540*t*
- Myocardial ischemia, 694
- Myoclonus, opioids causing, 266
- Myofascial pain, 489
- syndrome, 568–572, 569*t*
  - trigger points, 571*f*
- N
- Nabumetone
- bleeding disorder and, 144
  - dosage of, 140, 140*t*
- Nalbuphine
- characteristics of, 189
  - equianalgesic doses of, 242*t*
  - labor and delivery and, 618
  - pregnancy and, 614
- Nalfon; *see* Fenoprofen
- Nalmefene
- opioid overdose and, 269
  - procedural analgesia with, 379*t*, 380
- Naloxone
- administration of, 269, 270*t*
  - cancer-related pain and, 541–542
  - inappropriate use, 269
  - opioid overdose and, 269, 270

- Naloxone—cont'd  
 procedural analgesia with, 379*t*, 380
- Naltrexone, 460–461
- Naprosyn; *see* Naproxen
- Naproxen  
 dosage of, 139*t*  
 for child, 143*t*  
 overdose of, 152
- Naratriptan for migraine, 554*t*
- Narcotic, definition of, 104, 162, 429; *see also* Opioid analgesic
- Naropin; *see* Ropivacaine
- Nasal spray, 112
- National Association of Orthopaedic Nurses, 55
- National Hospice Organization, 11
- National Institute of Arthritis, Musculoskeletal and Skin Diseases Information Clearinghouse, 517
- National Institute of Drug Abuse, 430
- National Institutes of Health, 274
- National Neurofibromatosis Foundation, Inc., 517
- National Vulvodynia Association, 517
- Natural childbirth, 609
- Natural killer cell, 29
- Nausea and vomiting  
 alcohol withdrawal and, 457  
 elderly and, 695  
 ergotamine withdrawal and, 559  
 migraine and, 553  
 opioids causing, 261, 262–265, 262*t*–263*t*
- Nebulized opioid, 195*t*, 203
- Neck pain, myofascial, 571*f*
- Necrosis, aseptic, 539
- Necrotizing enterocolitis, 660
- Needle  
 intraspinal, 214–220, 218*f*  
 complications of, 233  
 subcutaneous infusion, 211*t*
- Needs assessment tool, 724–726
- Nefazodone, 305*t*, 306*t*
- Neglect of elderly, 706
- Nelfinavir, 567
- Nembutal; *see* Pentobarbital
- Neonatal abstinence syndrome, 616–617, 631–632
- Neonatal Facial Coding System, 641
- Neonatal Infant Pain Scale, 644–645, 650
- Neonatal intensive care unit, 637–638
- Neonatal period, 627
- Neonate; *see also* Infant  
 abstinence syndrome in, 616–617  
 definition of, 627  
 EMLA in, 376–377  
 fentanyl in, 654*t*  
 long-term effects of pain in, 634–635  
 memory of pain in, 30  
 morphine in, 654*t*  
 surgery in, opioid for, 24–25
- Nerve block  
 cancer-related pain and, 541  
 chronic pain and, 510, 511  
 clonidine, 337*t*  
 herpes zoster and, 563
- Nerve block—cont'd  
 in infants, 657*t*  
 intraspinal opioid versus, 25  
 local anesthetic for, 367–378; *see also* Local anesthetic  
 osteoporosis and, 575  
 pudendal, 621  
 subarachnoid space, 619–620
- Nerve block clinic, 11
- Nerve fiber, 577
- Nerve root, arachnoiditis and, 596
- Neuralgia  
 definition of, 16, 302  
 postherpetic, 561–564, 561*f*
- Neuraxial opioid, 621
- Neurochemical disorder, 547
- Neuroleptic, 332–334  
 as adjuvant analgesic, 316–317  
 adverse effects of, 333  
 examples of, 305*t*  
 indications for, 334  
 mechanism of action of, 333
- Neuroleptic malignant syndrome, 333
- Neurologic disorder  
 Ehlers-Danlos syndrome and, 543  
 Lyme disease and, 601  
 migraine and, 553  
 multiple sclerosis and, 602–603  
 reflex sympathetic dystrophy and, 581–584
- Neurolytic block, celiac plexus, 581
- Neuron, afferent, 16
- Neuronal “wind-up,” 23
- Neurontin; *see* Gabapentin
- Neuropathic pain, 19*t*,  
 adjuvant analgesics for, 109*t*, 113  
 anticonvulsants and, 321–324  
 antidepressants and, 310, 317, 317*t*  
 lancinating pain and, 320–324, 321*t*  
 local anesthetics and, 317–320  
 baclofen for, 324  
 burn injury and, 530  
 cancer-related, 537, 538*t*, 541  
 characteristics of, 23  
 classification of, 19*t*  
 definition of, 16, 162, 675  
 in elderly, 696, 699*t*  
 anticonvulsants for, 697  
 herpes zoster and, 563  
 HIV and, 567  
 lidocaine for, 338–339  
 n-methyl-D-aspartate receptor blockers for, 328–330  
 peripheral, 16, 576–579, 577*f*  
 rating scale for, 75, 76–77  
 wound, 592
- Neurophysiologic adaptation in addiction, 452
- Neuropsychologic toxicity of corticosteroid, 312
- Neurotensin, 23
- Neurotoxic agent, injection of, 233  
 prevention of intraspinal, 234*t*
- Neurotransmitter  
 opioid receptors and, 165–166

- Neurotransmitter—cont'd  
 transmission of pain and, 22
- Newborn; *see* Infant; Neonate
- Nifedipine, 305*t*
- Nipple pain, 622
- Nitrous oxide  
 burn injury and, 529*t*  
 procedural analgesia with, 387*t*, 388–389
- NMDA; *see* N-methyl-D-aspartate
- NMDA receptor antagonist, 305*t*  
 as adjuvant analgesic, 317*t*  
 neuropathic pain and, 321*t*, 328–330
- N-methyl-D-aspartate  
 as adjuvant analgesic, 317*t*  
 definition of, 302  
 transmission of pain and, 22
- Nociceptive pain, 18–23  
 cancer-related, 533, 537, 541  
 classification of, 19*t*  
 definition of, 16  
 elderly and, 696  
 intraspinal anesthesia and, 222  
 modulation of, 21*f*, 22–23  
 nonsteroidal antiinflammatory drugs and, 130  
 perception of, 21*f*, 22  
 transduction of, 18, 21*f*, 22  
 transmission of, 20*t*, 21–22, 21*f*  
 wound, 592–593, 593*t*, 594
- Nociceptor, 16, 162
- Nondrug pain treatments, 399–425  
 burn injury and, 530–531  
 for child, 421, 422*t*  
 for childbirth, 617  
 in clinical practice, 421–425  
 cutaneous stimulation as, 405–417; *see also* Cutaneous stimulation  
 distraction as, 412–417  
 for elderly, 700  
 for infant, 658–661  
 misconceptions about, 401*t*  
 relaxation as, 417–421  
 role of, 400–405  
 selection of, 404*t*
- Nonmalignant pain  
 cancer pain versus, 47–48  
 chronic; *see* Chronic pain
- Nonnarcotic; *see* Nonopioid analgesic
- Nonnutritive sucking, 659
- Nonopioid analgesics, 105*f*; *see also* Acetaminophen; Aspirin;  
 Nonsteroidal antiinflammatory drugs  
 caffeine with, 316  
 in children, 142–148, 143*t*  
 clinical considerations for, 108–110  
 comparison of, 114*t*  
 definition of, 104, 130  
 dosing information, 133*t*, 138, 139–140*t*, 140–143, 142*t*  
 for children, 143*t*  
 elderly and, 689–691  
 generic and brand names, 138*t*  
 indications for, 131–134, 133*t*
- Nonopioid analgesics—cont'd  
 infant and, 653–654  
 mechanism of action of, 130  
 misconceptions about, 131*t*  
 opioid combined with; *see* Combination analgesic  
 pain mechanism affected by, 108  
 perioperative/postoperative, 145  
 polypharmacy and, 304  
 selection of, 142*t*  
 side effects, 134–138, 135*t*  
 titration of, 122  
 trade and generic names of, 138*t*
- Nonprescription drug; *see* Over-the-counter drug
- Nonsteroidal antiinflammatory drugs (NSAIDs)  
 for acute versus chronic pain, 138  
 adverse effects of, 145–148  
 analgesic action, 132*f*  
 analgesic history and, 140  
 ankylosing spondylitis and, 596  
 antipyretic effect of, 144  
 arthritis and, 526  
 aspirin allergy and, 144  
 bleeding disorder and, 144  
 for bone pain, 326  
 breast feeding and, 142, 623  
 for child, 142–144  
 choice of, 110  
 clinical considerations for, 108–110  
 combination analgesics with, 116  
 cost of, 141  
 definition of, 104, 130  
 dosages, 139–140*t*  
 frequency of, 140–141  
 guidelines for, 142  
 titration of, 141–142  
 drug combinations with, 148–150  
 elderly and, 689–691, 695, 698, 699*t*  
 alternative approaches, 690*t*  
 cognitively impaired, 704  
 long-term use, 689*t*  
 examples of, 109*t*  
 fibromyalgia and, 548–549  
 gastrointestinal function and, 27  
 hemophilia and, 599  
 indications for, 108–110, 131–134, 133*t*  
 infant and, 654  
 mechanism of action of, 130  
 migraine and, 554*t*  
 misconceptions about, 131*t*  
 nonprescription, 148–150, 151*t*  
 overdose of, 150–152  
 patient/family teaching about, 152, 153–158, 157–158*t*  
 perioperative, 144–148, 146*t*  
 metabolic response and, 24  
 pregnancy and, 142, 611, 613  
 procedural analgesia with, 380–381  
 response to, 140  
 routes of administration for, 110, 141  
 side effects of, 134–138  
 temporomandibular dysfunction and, 590



- Nonsteroidal antiinflammatory drugs (NSAIDs)—cont'd  
transduction of pain and, 18
- Norepinephrine, 368
- Norflex; *see* Orphenadrine
- Normeperidine, 226
- Norpramin; *see* Desipramine
- Norpropoxyphene, 169, 180*t*, 187, 192
- North American Chronic Pain Association of Canada, 517
- Nortriptyline, 305*t*, 306*t*  
as adjuvant analgesic, 307  
breast feeding and, 623–624  
for child, 341*t*  
indications and dosages of, 343*t*  
patient education about, 348–349*t*  
side effects of, 308  
tension headache and, 555*t*
- Noxious stimulus, 16
- NSAIDs; *see* Nonsteroidal antiinflammatory drugs
- Nubain; *see* Nalbuphine
- Nulliparity, 609
- Numby Stuff, 377–378
- Numerical rating scale, 63*f*, 65–75  
cultural differences and, 98  
definition of, 36  
examples of, 68*f*–73*f*
- Numorphan; *see* Oxymorphone
- Nuprin; *see* Ibuprofen
- Nurse  
certification of, 11, 13  
expectations about pain of, 44  
pain resource, 5  
role of, 125, 128
- Nurse-activated dosing, 177
- Nurse-based patient-controlled analgesia program, 742–743
- Nursing admission assessment, 58
- Nursing home, 675, 681–683
- O
- Obesity, respiratory complications and, 26
- Obsessive compulsive disorder, 436
- Obstetrics/gynecology  
Ehlers-Danlos syndrome and, 543  
pregnancy and; *see* Labor and delivery; Pregnancy
- Obstruction, bowel, 326–327, 327*t*
- Occlusal therapy, 591
- Occupational therapy in arthritis, 526
- Octreotide  
malignant bowel obstruction and, 327, 327*t*  
pancreatitis and, 581
- Ocular procedure, 372–373
- Office of National Drug Control Policy, 431
- Ointment, local anesthetic, 332
- Older Americans Act, 706
- Oncology Nursing Society  
education resources of, 6  
placebo and, 55, 56
- On-line computerized database, 612
- Operative site bleeding, 146
- Ophthalmic procedure, 372–373
- Opiate, definition of, 104; *see also* Opioid analgesic
- Opinion leader, 712, 716
- Opioid analgesics, 105*f*, 161–293  
for acute pain, 178*t*  
addiction to; *see* Addiction  
adverse effects, 146*t*  
antidepressant with, 308  
around the clock dosing of, 175  
in cognitively impaired elderly, 704  
rescue dose and, 244–246  
arthritis and, 526  
breast feeding and, 623  
cancer-related pain and, 541; *see also* Cancer-related pain  
cessation of therapy with, 270–271  
characteristics of intraspinal, 223–224*t*  
in child, 143*t*–144*t*  
for chronic pain, 178*t*, 496–499  
classification of, 165  
in combination; *see* Combination analgesic  
comparison of, 113–114, 114*t*  
definition of, 36, 130, 162, 363, 429  
detoxification and, 459*t*  
documentation for, 272, 273  
dosages, 133*t*  
starting, 244*t*  
rescue, 245*t*  
elderly and, 691–695, 694, 699*t*  
cognitively impaired, 701  
endogenous  
composition and function of, 165  
definition of, 16  
modulation of pain and, 22–23  
equianalgesic dosage of, 133*t*, 174, 240–243  
examples of, 109*t*  
fibromyalgia and, 549  
herpes zoster and, 562–563  
HIV and, 565, 567  
immune system and, 29–30  
infant and, 654–656, 654*t*  
weaning flowsheet, 632*t*  
intraspinal characteristics, 223–224*t*  
labor and delivery and, 618, 619–620  
mechanism of action of, 165–166  
misconceptions about, 163–164*t*  
infant and, 631  
potency and, 170  
mu agonist characteristics, 179–180*t*  
newer, 190–191  
nonsteroidal antiinflammatory drug with, 131*t*, 132, 149*t*  
oral administration of; *see* Oral administration, of opioid  
osteoporosis and, 574–575  
outpatient, 755*t*  
pain  
mechanism affected by, 108  
treatment definitions, 462*t*  
pancreatitis and, 581  
patient education about, 272–292; *see also* Education, patient  
patient-controlled, 249–255; *see also* Patient-controlled  
analgesia  
perioperative, 145  
metabolic response and, 24–25

- Opioid analgesics—cont'd
- peripheral neuropathy and, 578–579
  - pharmacology of, 166–174
    - absorption and metabolism and, 168
    - addiction and, 173; *see also* Addiction
    - equianalgesia and, 174
    - equivalent products, 197*t*
    - pharmacokinetics of, 167–170
    - pharmacodynamics of, 170–174
    - physical dependence and, 173
    - potency and efficacy and, 170–171
    - tolerance and, 169–173
  - polypharmacy and, 304–306
  - pregnancy and, 613–614
  - PRN dosing of, 175
  - for procedural pain, 378–380, 399*t*
  - receptors; *see* Opioid receptors
  - rectal administration of, 205*t*
  - as rescue analgesia, 134
  - respiratory effects and, 26
  - routes of administration of, 195–196*t*
    - intranasal, 203
    - intraspinal, 213–239; *see also* Epidural analgesia; Intraspinal analgesia; Intrathecal administration
    - nebulized, 203
    - oral, 194–203; *see also* Oral administration
    - parenteral, 209–213; *see also* Intramuscular administration; Intravenous administration; Subcutaneous administration
    - rectal, 204–205
    - stomal, 205–206, 206*t*
    - transdermal, 206–209
  - selection guidelines for
    - agonist-antagonist and, 188–190; *see also* Agonist-antagonist
    - mu agonist and, 178–188; *see also* Mu agonist
    - new drugs and, 190–191
    - patient characteristics in, 191–194
    - route of administration and, 239–240
    - starting dose and, 240–246
  - sickle cell disease and, 585, 587
  - side effects of, 261–270
    - alternatives for, 256*t*
    - biliary spasm as, 265
    - constipation as, 262
    - epidural analgesia and, 254*t*–255*t*
    - mental status changes as, 263, 267–268
    - myoclonus as, 266–267
    - nausea and vomiting as, 261, 263, 264–265
    - options for, 256*t*
    - preventing and managing, 263–264*t*
    - prevention, 262–264*t*
    - pruritus as, 263, 265–266
    - respiratory depression as, 268–270
    - sedation as, 267–268
    - urinary retention as, 266
  - switching of, 257*t*
    - from epidural to intravenous, 257–259
    - from multiple drugs to single, 259–260
    - from one route to another, 257–259
    - to another opioid, 253, 255–257
  - temporomandibular dysfunction and, 590
- Opioid analgesics—cont'd
- undertreatment of pain and, 9
  - unwarranted withholding of, 271–272; *see also* Undertreatment of pain
  - withdrawal of, 494–496
  - written agreement about, 753–755
- Opioid antagonists, 162, 363; *see also* Naloxone
- inappropriate use of, 269–270
- Opioid dose-sparing effect, 130
- Opioid-naïve patient
- epidural analgesia in, 225
  - infusion and, 81, 251
  - patient-controlled analgesia for, 250, 252*t*
  - respiratory depression in, 145, 268–269
  - tolerant versus, 172–173
- Opioid receptors, 165–166, 165*f*, 166*f*, 167*t*
- Opioid treatment, long term, 490–499, 498*t*
- Oral administration
- clonidine, 336
  - of cocaine, 316
  - of local anesthetic, 317–320
    - for child, 341*t*
  - of opioid, 194–201
    - disadvantages of, 196
    - formulations for, 196–199
    - intravenous analgesia and, 258–259
    - methadone, 185
    - patient-controlled, 199–200
    - postoperative pain and, 201
    - transdermal fentanyl and, 209*t*
    - transmucosal, 201–203
  - as optimal route, 121
  - tramadol and, 190
- Oral transmucosal fentanyl citrate, 202*f*, 207*f*, 209*t*
- for procedural pain, 378, 379*t*
  - as rescue analgesic, 245*t*
- Organ failure, 192
- Organizations, professional, 12*t*
- acronyms for, 2
  - growth of, 11
- Orphenadrine, 305*t*
- as muscle relaxant, 327, 328
  - musculoskeletal pain and, 327*t*
  - nonopioids with, 150
- Orthodontic therapy, 591
- Orthopedic surgery, 678*t*
- Orthostatic hypotension, antidepressant and, 308
- in elderly, 697
- Orudis; *see* Ketoprofen
- Osteoarthritis, 523–527
- affected joints, 525*f*
  - alternative treatment for, 690*t*
  - joint characteristics, 524*f*
  - oxycodone for, 692
- Osteoporosis, 572–576
- assessment of, 573–574
  - definition of, 572–573
  - fracture sites in, 573*f*
  - pain characteristics of, 573
  - pain management of, 574–575

- Osteoporosis—cont'd  
 posture in, 574*f*
- Osteoporosis and Related bone Diseases National Resource Center, 518
- OTFC; *see* Oral transmucosal fentanyl citrate
- Oucher rating scale, 63
- Outpatient  
 chronic pain and, 505  
 drug treatment and, 451*t*, 456, 458  
 patient information for, 752, 755
- Overdose  
 of nonsteroidal antiinflammatory drugs, 150–152  
 opioid, 269
- Over-the-counter drug  
 arthritis and, 526  
 list of, 125  
 nonopioid, 148–150, 148*t*–149*t*, 150*t*  
 rebound headache from, 559
- Oxaprozin  
 brand name of, 138*t*  
 dosages of, 139*t*
- Oxazepam, 656*t*
- Oxicam, 139*t*
- Oxycodone  
 characteristics of, 180*t*, 186–187  
 elderly and, 692  
 equianalgesic doses of, 133*t*, 242*t*  
 fixed combination with, 117  
 oral, 198–199  
 patient information about, 287–290  
 pregnancy and, 614  
 switching from, 259, 260  
 transdermal fentanyl and, 209*t*
- Oxygen  
 cluster headache and, 559  
 cognitive impairment in elderly and, 701  
 headache and, 556–557  
 sickle cell disease and, 585  
 thermoregulation and, 26
- Oxymorphone  
 characteristics of, 180*t*, 187  
 equianalgesic doses of, 242*t*
- P
- Pacing, by patient, 504*t*
- Pain  
 addiction and, 429–430, 452; *see also* Addiction  
 anatomy and physiology of, 18–23  
 assessment of, 36–99; *see also* Assessment  
 tool, 60*f*, 60*t*  
 back  
 angiography and, 391  
 chronic, 473–474  
 psychiatric setting and, 475–476  
 breakthrough; *see* Breakthrough pain  
 care committee; *see* Pain care committee  
 cancer-related, 531–543; *see also* Cancer-related pain  
 cause, known versus unknown, 46–50  
 center, 514  
 centrally generated  
 classification of, 19*t*  
 definition of, 16  
 chronic; *see* Chronic pain  
 classification by inferred pathology, 19*t*  
 clinician's expectations about, 44–46  
 conditions causing, 522–607  
 ankylosing spondylitis, 595–596  
 arachnoiditis, 596  
 burn, 527–531  
 chronic fatigue syndrome, 597  
 Crohn's disease, 597–598  
 Ehlers-Danlos syndrome, 543–545  
 fibromyalgia syndrome, 545–550  
 headache, 550–560  
 hemophilia, 598–599  
 herpes zoster, 561–564  
 human immunodeficiency virus infection, 564–568  
 low back pain, 599–600  
 Lyme disease, 600–601  
 mastectomy, 537*t*, 604  
 mucositis, 601–602  
 multiple sclerosis, 602–603  
 myofascial pain syndrome, 568–572  
 osteoporosis, 572–576  
 pancreatitis, 579–581  
 peripheral neuropathy, 576–579  
 phantom limb, 603–604  
 poliomyelitis, 604–605  
 reflex sympathetic dystrophy, 581–584  
 sickle cell disease, 585–588  
 spinal cord injury, 606–607  
 temporomandibular joint disorder, 588–591  
 thoracotomy, 537*t*, 605–606  
 wound pain, 592–595  
 control record, 87–88*t*  
 crescendo, 335–340  
 deafferentation, 302  
 definition of, 16–17  
 denial of, 89, 92  
 documentation of responses, 459*t*  
 facilities, 10–11, 514, 514*t*  
 harmful effects of, 23–32, 24*t*  
 on cardiovascular system, 25–26  
 on cognitive function, 28–29  
 on development, 30  
 on endocrine and metabolic system, 23–25  
 on future pain, 30–31  
 on gastrointestinal system, 27–28  
 on genitourinary system, 27  
 on immune system, 29–30  
 on musculoskeletal system, 27–28  
 on quality of life, 31–32  
 on respiratory system, 26–27  
 in infant, 629–669; *see also* Infant  
 intensity, 95*t*  
 inventory, 61*f*, 61*t*  
 known versus unknown cause of, 46–48

## Pain—cont'd

- Knowledge and attitude survey, 728*t*
  - management; *see* Pain management
  - mechanism of, 16–32
    - misconceptions about, 17*t*
    - nonopioids and, 108
  - myofascial, 489
  - neuropathic; *see* Neuropathic pain
  - nociceptive, 18–23, 19*t*; *see also* Nociceptive pain
  - nondrug treatment of, 399–425; *see also* Nondrug pain treatment
  - nonmalignant; *see* Chronic pain
  - pathology, inferred, 19*t*
  - perception, 16
    - in elderly, 675
  - physiology of, resources about, 17
  - in pregnancy, 615–616
  - procedural, 362–395; *see also* Procedural pain management
  - psychogenic, 36, 49–50
  - rating scales; *see* Pain rating scales
  - relief diary, 200
  - report, 90–91*t*
  - resource nurse (PRN), 5, 741*t*, 742
    - dosing, 175
  - response, acute pain model of, 43–46
  - screen, 96*t*
  - services, 739–740
    - creation of, 11
  - somatic, 19*t*
  - subjectivity of, 5, 9
  - supratentorial, 49–50
  - sympathetically maintained, 330
  - tabetic, 302
  - threshold, 42
  - tolerance, high versus low, 42–43
  - transmission of, 16, 19*t*, 20–21*f*, 22–23
    - of antidepressant, 309*f*
    - definition of, 106*f*
    - illustration of, 21, 107*f*
    - for local anesthetics, 319*f*
    - process of, 22
  - types of, 17–18, 19*t*
    - definitions of, 16
    - treatment approaches to, 18
  - undertreatment of; *see* Undertreatment of pain
  - visceral, 19*t*
- Pain care committee, 713, 715–737
- composition of, 716–717
  - data collection by, 720–730
  - establishment of, 715–716
  - ground rules for, 718*t*
  - leadership of, 717
  - mission statement of, 717–718, 718*t*
  - problems with, 718–720
  - resources for, 717*t*
  - responsibilities of, 730–737
- Pain management, 711–742
- audit of, 727
  - barriers to, 2–10

## Pain management—cont'd

- barriers to—cont'd
    - health care professionals as, 4–10
    - institutional, 713
    - lack of accountability and, 3–4
    - patient and family as, 10
  - information gathering for, 515*t*
  - institutional commitment to, 715–743
    - administrative rules and, 738
    - assessment standards, 734*t*
    - cause and effect diagram, 722–723*f*
    - clinical pathways and, 738–739
    - knowledge and attitude survey, 728*t*
    - library, 738*t*
    - need for change and, 720–730
    - needs assessment tool, 724–726*t*
    - nurse-based PCA programs and, 742–743
    - pain care committee and, 715–720, 730–737
    - pain resource nurse programs and, 742
    - pain services and, 739–740
    - patient questionnaire, 729*t*
    - quick reference guide, 736*t*
    - role model programs and, 740–742
  - misconceptions about, 712–713, 712*t*
  - patient questionnaire about, 729
  - patient teaching checklist, 273*t*
  - program for, 515
  - progress in, 10–13
  - quality improvement, 713–715, 714–715*t*, 716*t*
    - data analysis tools, 721*f*
  - teaching checklist, 273
  - team approach to, 89*t*
  - in terminally ill, 272
- Pain rating scales; *see also* Assessment, tool
- definition of, 36
  - faces, 64–65*f*, 67*f*
  - failure to obtain, 36, 38
  - for infant, 639–649
  - neuropathy, 76–77*t*
  - preferred, 37
  - selecting, 66*t*
  - teaching use of, 74*t*
  - translations of, 68–73*f*
- Palliation, local anesthetics for, 320
- Pamelor; *see* Nortriptyline
- Pamidronate, 325
- Panadol, 148*t*
- Pancreatitis, 579–581
  - autodigestion, 580*f*
  - pain mechanisms, 580*t*
- Paracervical block, 621
- Parafon Forte; *see* Chlorzoxazone
- Paranoia, opioids causing, 263*t*
- Paravertebral sympathetic ganglion blockade, 583–584
- Parent of infant, 668
- Parenteral administration; *see also specific routes*
- of ketamine, 337–338
  - of ketorolac, 133
    - in child, 144

- Parenteral administration—cont'd  
 of ketorolac—cont'd  
   postoperative, 145  
 of lidocaine, 338–339  
 of local anesthetic, 317–320  
 of nonsteroidal antiinflammatory drug, 131*t*  
 of opioid, 209–213  
   labor and delivery and, 619, 621  
 of phenytoin, 339
- Paresthesia, 162, 302
- Parkland burn pain management pathway, 529*t*, 530
- Paroxetine, 306*t*, 307  
 indications and dosages of, 343*t*
- Paroxysmal  
 definition of, 302  
 sweats in alcohol withdrawal, 457
- Patch  
 blood, 232  
 fentanyl, 277–278  
 local anesthetic, 332  
 transdermal, 207–209
- Patients  
 assistance program for, 194  
 as barrier to pain management, 10  
 education; *see* Education, patient  
 educational materials, 274*t*  
 information for, 126–127*t*  
 pain relief diary, 200*t*  
 report of pain by, 38–40  
 rights of, 13*t*  
 surveying of, 721, 729, 730
- Patient-controlled analgesia (PCA), 175–177, 211, 248–253  
 for acute pain, 754*t*  
 appropriateness of, 176–177  
 breast feeding and, 623  
 burn injury and, 529*t*  
 cardiovascular effects and, 25  
 with continuous infusion, 251–252  
 dosage calculation for, 122, 250*t*  
   pediatric, 255*t*  
 for elderly, 693  
   cognitively impaired, 702  
 epidural, 220, 224–227, 225*t*  
 hydromorphone for, 265  
 initiation in PACU, 252–253  
 intraspinal, 220, 224–226  
 IV use, 176*t*, 291–292*t*  
 lidocaine for, 339  
 nurse-based program for, 742–743  
 opioid-naïve adult ranges, 252*t*  
 oral, 199–200, 199*t*  
 patient information about, 291–292  
 patient selection for, 176–177  
 pediatric, 253, 255*t*  
 procedural, 388  
 pump use, 177*t*, 249*t*  
 respiratory effects and, 26  
 side effect reduction, 254–255*t*  
 starting prescription for, 250–252, 250*t*  
 subcutaneous continuous infusion and, 210–213
- Patient-controlled analgesia—cont'd  
 titration of dose and, 246  
 unconventional use of, 177  
 written agreement for, 754–755
- Patient's bill of rights, 13*t*
- Paxil; *see* Paroxetine
- PCA; *see* Patient-controlled analgesia
- P4502D6, 181*n*
- Pediatric patient; *see* Child
- Pediodicals, clinical, 738
- Pemoline, 305*t*
- Penile block for circumcision, 376
- Pentamorphone, 190
- Pentazocine  
 characteristics of, 189–190  
 elderly and, 693, 699*t*  
 equianalgesic dosage of, 133*t*, 242*t*  
 mild pain and, 191
- Pentobarbital  
 in elderly, 699*t*
- Peptic ulcer  
 corticosteroid causing, 312  
 in elderly, 698–699  
 elderly and, 689
- Perception of pain  
 antidepressants and, 309*f*  
 definition of, 16, 106*f*  
 in elderly, 675  
 local anesthetics and, 319*f*  
 process of, 22
- Percocet, 116, 134
- Percogesic Coated, 148*t*
- Perinatal period, 609  
 definition of, 627
- Periodicals, clinical, 5, 8*t*, 738
- Perioperative analgesia  
 gastrointestinal function and, 28  
 nonsteroidal antiinflammatory drugs for, 133, 144–148  
   adverse effects of, 145–148, 145–148, 146*t*  
   effectiveness of, 144–145  
 opioid, 24–25
- Peripheral nerve block; *see* Nerve block
- Peripheral nerve in infant, 635
- Peripheral neuropathy, 16, 576–579  
 assessment of, 577  
 cancer-related, 538*t*  
 description of, 576–577, 577*f*  
 pain management of, 577–579
- Peripheral vascular disease, 696
- Peripherally generated pain, 19*t*
- Perphenazine, 699*t*
- Persistent vegetative state, 94–95
- Phantom limb pain, 603–604  
 in elderly, 694  
 previous acute pain and, 30
- Pharmacodynamics in infant, 652–653
- Pharmacokinetics  
 HIV and, 567  
 infant and, 652–653  
 of opioids, 167–170

- Pharmacology of opioid analgesic, 166–174; *see also* Opioid analgesic, pharmacology of equivalent products, 197*t*
- Pharmacotherapy for drug abuse, 442*t*, 443
- Phenacetin  
liver toxicity of, 135  
renal failure caused by, 135
- Phenergan, 380
- Phenobarbital  
alcohol, 458  
opioids and, 193
- Phenothiazine, 113  
opioids and, 193
- Phenoxybenzamine, 305*t*
- Phentolamine, 584
- Phenylbutazone, 699*t*
- Phenyltoloxamine citrate, 150
- Phenytoin, 305*t*  
adverse effects of, 323  
for child, 341*t*  
for crescendo pain, 339  
indications and dosages of, 342*t*  
for lancinating pain, 324  
neuropathic pain and, 321*t*  
opioids and, 193  
overview of, 321–322  
parenteral, 339
- Physical abuse of elderly, 706
- Physical appearance in pain assessment, 57  
in infant, 633*f*, 634*f*
- Physical dependence  
addiction versus, 434  
definition of, 50, 162, 429  
opioid and, 173
- Physical rehabilitation  
chronic pain and, 503, 505  
postoperative, 740
- Physical therapy  
ankylosing spondylitis and, 595–596  
arthritis and, 526  
chronic pain and, 503, 505  
Ehlers-Danlos syndrome and, 545  
fibromyalgia and, 549  
reflex sympathetic dystrophy and, 583  
temporomandibular dysfunction and, 591
- Physiologic response to pain, 95  
acute pain model and, 45
- Physiology of pain, resources about, 17
- Pimozide, 305*t*  
dosages of, 344  
indications for, 334, 344  
neuropathic pain and, 321*t*
- Pinch-grasp injection technique, 395*f*
- PIPP; *see* Premature Infant Pain Profile
- Piroxicam, 139*t*
- Placebo(s)  
chronic pain and, 492  
controlled trial, 302  
definition of, 36  
EMLA versus, 376
- Placebo(s)—cont'd  
misconceptions about, 54–55  
recommendations about, 55–56  
transdermal fentanyl and, 209  
use of, 56*t*, 57*t*
- Placenta, 610
- Plasma protein, 169
- Platelet, 110, 138, 144
- Plexus  
brachial  
cancer-related pain in, 535*t*  
radiation fibrosis of, 540*t*  
celiac, 581  
lumbar, 535*t*  
lumbosacral, 540*t*  
sacral, 536*t*
- Policy on placebo use, 56
- Poliomyelitis, 604–605
- Polymyalgia rheumatica, 696
- Polyneuropathy  
definition of, 19*t*  
in elderly, 696
- Polypharmacy; *see also* Combination analgesia  
adjuvant analgesics and, 304  
in elderly, 698–699  
HIV and, 567  
misconceptions about, 105*t*
- Ponstel; *see* Mefenamic acid
- Positioning of infant, 658–659
- Postchemotherapy pain, 538*t*–539*t*
- Postdural puncture headache, 232
- Posterior deltoid trigger point, 571*f*
- Postherpetic neuralgia, 31, 561–564, 561*f*, 562  
in elderly, 696
- Postmastectomy pain, 537*t*, 604
- Postnatal age, 649
- Postoperative pain  
cesarean section, 622–623  
in child, 143*t*, 144  
dextroamphetamine for, 339  
in elderly, 680, 690–691  
cognitively impaired, 701  
nonsteroidal antiinflammatory drugs for, 133, 143*t*  
opioid and, 191–192  
oral analgesics for, 201  
patient-controlled analgesia for, 250–251, 252–253  
preemptive analgesia and, 120–121  
rehabilitation program for, 680, 740  
transdermal fentanyl for, 209
- Postpartum pain, 621–623
- Postpolio pain, 604–605
- Postradiation pain, 540*t*
- Postthoracotomy pain, 605–606
- Posttraumatic stress, 468  
burn injury and, 529*t*, 531
- Posture, stooped, 574*f*
- Potency  
definition of, 162  
of opioid, 170–171  
methadone, 186

- Potential  
 action  
   definition of, 16  
   transduction of pain and, 18  
 resting, 16, 18
- Prazosin, 305*t*  
 postmastectomy pain and, 604
- Preceptorships, 740, 741*t*
- Precontemplation stage of drug treatment, 447–448, 447*t*
- Prednisone, 305*t*  
 breast feeding and, 624  
 cluster headache and, 556*t*  
 migraine and, 555*t*
- Preemptive analgesia  
 advantages of, 120–121  
 characteristics of, 174–175  
 for child, 143*t*–144  
 concept of, 174–175  
 definition of, 162, 363  
 nonsteroidal antiinflammatory drugs for, 133, 145
- Pregnancy, 609–623  
 acetaminophen and, 611, 613  
 adjuvant analgesic in, 614–615  
 analgesics  
   opioid, 613–614  
   references and resources, 611–612*t*  
   use during, 610*t*, 611–615  
 back pain in, 615–616  
 Braxton Hicks contractions in, 616  
 childbirth pain management and, 617–621  
 FDA risk classification, 609–610, 611*t*  
 headache in, 615  
 lactation classifications, 623*t*  
 maternal-placental-fetal drug transfer and, 610–611, 613*f*  
 misconceptions related to analgesic use, 610  
 nonsteroidal antiinflammatory drugs and, 142  
 pain management resources, 611*t*  
 postpartum pain and, 621–623  
 pyrosis in, 616  
 round ligament pain in, 615  
 sickle cell disease and, 616  
 substance abuse and, 616–617
- Premature Infant Pain Profile (PIPP), 642, 645*t*, 650; *see also*  
 Infants; Preterm infants
- Preoperative analgesia, nonsteroidal antiinflammatory drugs  
 for, 145
- Preoperative medication, nonsteroidal antiinflammatory  
 drugs for, 133
- Prescribing of opioid analgesics, 751–755
- Prescription analgesic, list of, 125
- Pressure  
 on injection site, 394  
 intracranial, corticosteroids for, 312  
 wound pain and, 593
- Preterm infants, 609; *see also* Infants  
 CRIES score, 644*t*  
 definition of, 627  
 intensive care interventions, 662–663*f*  
 minimizing pain in, 661  
 opioid in, 655
- Preterm infants, 609—cont'd  
 pain in, 637–638  
   behavior, 635  
   management guidelines, 664–667*t*  
 PIPP, 645*t*
- Prilocaine  
 circumcision and, 637  
 in EMLA; *see* EMLA  
 eutectic mixture, 375*t*
- Primary afferent neuron, 16
- Primigravida, 609
- Primipara, 609
- Pruritus, 265–266  
 use of antagonists and agonist-antagonists, 265–266
- Privileging system, 712
- PRN; *see* Pain resource nurses
- Procaine  
 elderly and, 698  
 infusion of, 339
- Procedural pain management, 363–395  
 angiography and, 390  
 assessment in, 366–367  
 barbiturates for, 381, 386  
 barriers to, 363  
 benzodiazepines for, 381, 385*t*  
 burn injury and, 529*t*  
 cancer treatment and, 537, 537*t*–539*t*  
 chloral hydrate, 386  
 conscious sedation, 382–378  
 general anesthetics for, 386–389  
 goals of, 365  
 informed consent and, 365  
 intramuscular injection and, 391–395  
 iontophoresis, 377–378  
 local anesthetics for, 367–378; *see also* Local anesthetic  
 misconceptions about, 364*t*  
 need for, 363–365, 365*t*  
 nondrug approaches to, 389–390  
 opioids for, 378–381  
 patient education and, 365–366  
 refrigerant sprays, 377  
 suturing and, 395  
 wound and, 593
- Process, definition of, 712
- Prochlorperazine, migraine and, 554*t*
- Professional education, resources for, 6–7*t*
- Professional organization  
 acronyms for, 2  
 focus on pain, 12*t*  
 growth of, 11
- Promethazine, 695
- Prophylaxis  
 migraine and, 553, 556  
 for NSAID-induced ulcer, 137  
 for perioperative/postoperative pain; *see* Preemptive analgesia
- Propofol  
 patient-controlled analgesia with, 388  
 procedural analgesia with, 387–388, 387*t*
- Propoxyphene  
 characteristics of, 187–188

- Propoxyphene—cont'd  
 elderly and, 693, 699t  
 equianalgesic dosage of, 133t, 242t  
 pregnancy and, 614
- Propranolol, 305t  
 migraine and, 555t, 556
- Proprioceptive receptor, 592
- Propionic acid derivative, 139t; *see* Ibuprofen; Ketoprofen;  
 Naproxen
- Propoxyphene, 180t
- Prostaglandin  
 nonsteroidal antiinflammatory drugs and, 130, 136  
 transduction of pain and, 18
- Prostate cancer, 532t  
 age and, 678t
- Protease inhibitor, 567
- Protein binding  
 in elderly, 688, 690  
 opioids and, 169
- Protein synthesis, muscle, 25
- Protocol for infant, 664–667
- Proxy pain rating, 95
- Prozac; *see* Fluoxetine
- Pruritus, opioids causing, 263t, 265–266
- Pseudoaddiction, 51, 173–174
- Pseudorheumatism, steroid, 312
- Psilocybin, 433
- Psychiatric disorders  
 with alcohol addiction, 436–437, 436t, 437t  
 nonmalignant pain and, 476t
- Psychiatric setting, 475–476
- Psychogenic pain, 36, 49–50
- Psychologic dependence, 51, 173–174
- Psychologic factors  
 chronic pain and, 499  
 fibromyalgia and, 546–547  
 herpes zoster and, 562  
 Lyme disease and, 601  
 reflex sympathetic dystrophy and, 583
- Psychostimulant, 314–317  
 for child, 341t  
 examples of, 305t
- Pudendal nerve block, 621
- Pumps  
 external, 219f  
 implantable, 219f  
 for patient-controlled analgesia, 175–177, 249; *see also* Pa-  
 tient-controlled analgesia
- Puncture, dural, 232
- Pyranocarboxylic acid, 139t, 140t
- Pyrosis, pregnancy and, 616
- Q**
- Quality assurance, 712
- Quality improvement, 713–715, 721f  
 data analysis tools, 721f, 722–723f  
 data collection, 720–730  
 definition of, 712  
 guidelines, 716  
 pain care committee and, 715, 733–734
- Quality of life, 31–32
- Quality of pain, 59
- Quantitative sensory testing, 577
- Questionnaire  
 barriers, 89, 92, 93  
 CAGE, 705  
 chronic pain and, 478–487  
 coping strategies, 519  
 McGill pain, 577  
 patient, 729
- Quick reference guide for pain management, 736
- R**
- Race and culture in pain assessment, 57
- Radiation fibrosis, 540t
- Radionuclide for malignant bone pain, 325t, 326
- Randomized study, 302
- Ranitidine  
 in elderly, 699t  
 NSAID-induced ulcers and, 137
- Rash, herpes zoster, 562
- Rating scale for pain, 62–75; *see also* Pain rating scale
- Rebound headache, 559
- Receptors, opioid, 165–166, 165f, 166t, 167t  
 intraspinal anesthesia and, 222
- Recovery from addiction, 446, 459–460
- Rectal administration  
 of acetaminophen, 150t  
 in child, 143t, 150t  
 of nonsteroidal antiinflammatory drug, 131t  
 of opioids, 195t, 204–205, 205t
- Rectal cancer, 532t  
 age and, 678t
- Reference guide  
 formulary analgesic, 737  
 for pain management, 736
- Referral  
 chronic pain and, 513, 516  
 for drug treatment, 450, 451t
- Referred pain, 568–572
- Reflex sympathetic dystrophy, 581–584  
 in elderly, 697  
 typical, 582f
- Refrigerant spray, 377
- Refusal of pain treatment, 89, 92
- Regional anesthesia in infant, 656
- Regional blockade  
 labor and delivery and, 619  
 reflex sympathetic dystrophy and, 584
- Reglan; *see* Metoclopramide
- Regulation, federal, 9–10
- Rehabilitation  
 chronic pain and, 487–490, 503, 505  
 postoperative, 740
- Relafen; *see* Nabumetone
- Relapse in drug treatment, 436–438, 448
- Relaxation technique, 417–421  
 characteristics of, 419  
 chronic pain and, 500–501  
 deep breathing, 420t



- Relaxation technique—cont'd  
 imagining, 420*t*  
 indications for, 418–419  
 labor and delivery and, 617  
 massage as, 420–421, 421*t*  
 music, 391*t*  
 patient involvement in, 419–421  
 research about, 418
- Remifentanyl  
 characteristics of, 190  
 metabolism of, 192
- Renal function  
 acetaminophen and, 135–136  
 ketorolac and, 146–147  
 nonsteroidal antiinflammatory drugs and, 138  
 opioid analgesia and, 192  
 tramadol and, 191
- Repolarization, 16
- Rescue analgesic  
 dosage calculation for, 122, 244–246  
 nonopioids versus opioids as, 134  
 selection of, 121
- Research, terminology related to, 302
- Residential drug treatment, 442*t*, 446
- Respiratory depression, 264*t*, 267, 268–270  
 elderly and, 695  
 fear of, 9  
 infant and, 655*t*  
 labor and delivery and, 619  
 misconceptions about, 163*t*  
 naloxone for, 269  
 in opioid-naïve patient, 145  
 procedural analgesia and, 378, 380
- Respiratory effects of pain, 26–27
- Respiratory rate, infusion and, 81
- Responsiveness  
 to adjuvant analgesic, 304  
 to opioid, 171
- Resting potential, 16
- Restraint of infant, 659
- Retention, urinary, 266  
 epidural analgesia in child and, 239
- Revex; *see* Nalmefene
- Rhenium-186, 325, 326
- Rheumatoid arthritis, 523–525  
 affected joints, 525*f*  
 alternative treatment for, 690*t*  
 joint characteristics, 524*f*
- Rhinoplasty, gel pack for, 409*f*
- Rib fracture, fentanyl for, 26
- Rib pain, cancer-related, 535*t*
- Rid-a-Pain with Codeine, 149*t*
- Rightss, of patients with pain, 13, 13*t*
- Rimadyl; *see* Carprofen
- Ritalin; *see* Methylphenidate
- Ritonavir, 567
- Robaxin; *see* Methocarbamol
- Role model program, 740–742
- Romazicon; *see* Flumazenil
- Ropivacaine  
 in elderly, 694  
 injectable, 368  
 intraspinal, 228  
 for procedural pain, 369*t*
- Round ligament pain, 615
- Route of administration, 131*t*, 194, 195–196*t*  
 adjuvant analgesic and, 113  
 benzodiazepines and, 381  
 bioavailability of drug and, 169  
 buccal, 195*t*, 201  
 for elderly, 693–694  
 epidural, 213–239  
 individualization of regimen and, 121  
 infusion; *see* Infusion  
 intraarterial, 196*t*  
 intracerebroventricular, 196*t*  
 intramuscular; *see* Intramuscular administration  
 intranasal, 195*t*, 203  
 definition of, 162  
 effectiveness of, 25  
 midazolam and, 381  
 intrathecal, 196*t*, 213–239  
 for labor and delivery, 619–620  
 intraspinal, 213–239  
 intravenous; *see* Intravenous administration  
 nebulized, 203  
 for nonsteroidal antiinflammatory drugs, 110, 141  
 oral, 194–201  
 oral transmucosal, 201–203  
 patient's resistance to, 54  
 for procedural pain, 378  
 rectal, 204–205, 205*t*  
 reducing pain in, 391–394  
 stomal, 205–206  
 subcutaneous, 195*t*, 210–211, 211*t*, 212  
 sublingual, 195*t*, 201  
 switching of, 257–260  
 systemic, 302  
 transdermal, 206–209  
 transmucosal; *see* Transmucosal administration of opioid  
 vaginal, 206
- Rufen; *see* Ibuprofen
- Rule, administrative, 738
- S
- Sacral plexus, 536*t*
- Saddle block, 619
- Salicylate  
 dosage of, 139*t*  
 overdose of, 152
- Saline, bacteriostatic, 370
- Saliva, artificial, 602
- Salsalate  
 bleeding disorder and, 144  
 dosage of, 139*t*
- Samarium-153, 325, 326
- Sandostatin; *see* Octreotide
- Sansert; *see* Methylsergide
- Saquinavir, 567

- Scaleni trigger point, 571*f*
- Schizophrenia, alcohol addiction and, 436
- Sclerosis, multiple, 602–603
- Scopolamine, 327
- Secobarbital, 699*t*
- Seconal; *see* Secobarbital
- Secondary gain, 41–42
- Sedation
  - conscious, 382–384*t*
  - elderly and, 695
  - infusion and, 81
  - levels of, 267
  - misconceptions about, 364
  - opioids causing, 193, 267–268
  - procedural analgesia and, 378, 380, 381–386
  - procedures requiring, 365*t*
  - scale, 267*t*
- Sedatives
  - addiction to, 432*t*, 433
  - alcohol withdrawal and, 458
  - detoxification protocols, 458*t*
  - elderly and, 699*t*
  - infant and, 655
- Seizure, tramadol and, 191
- Selective serotonin reuptake inhibitor
  - as adjuvant analgesic, 307, 310
  - elderly and, 697
  - fibromyalgia and, 548
  - peripheral neuropathy and, 578
  - pregnancy and, 614
  - sexual dysfunction caused by, 309
  - side effects of, 308
- Sensorcaine; *see* Bupivacaine
- Sensory deficit with epidural anesthesia, 230*t*
- Sensory testing, quantitative, 577
- Sequential trial, 162, 302
- Serotonin, 23
- Serotonin antagonist, 555*t*
- Serotonin-receptor agonist, 553
- Sertraline, 305*t*, 306*t*
  - indications and dosages of, 343*t*
- Sex hormone in osteoporosis, 575
- Sexual dysfunction with antidepressant, 309
- Shingles, 561–564, 561*f*
  - chronic pain and, 31
- Shooting pain; *see* Lancinating pain
- Sickle cell disease, 585–588
  - pain examples, 586*f*
  - pregnancy and, 616
- Sickness Impact Profile, 519
- Side effects, of opioids analgesics, 261–270
  - biliary spasm as, 265
  - constipation as, 262
  - mental status changes as, 263, 267–268
  - myoclonus as, 266–267
  - nausea and vomiting as, 261, 263, 264–265
  - options for, 256*t*
  - pruritus as, 263, 265–266
  - respiratory depression as, 268–270
  - sedation as, 267–268
- Side effects, of opioids analgesics—cont'd
  - urinary retention as, 266
- Silent cry, 634*f*
- Simple descriptor rating scale, 63
  - numerical scale versus, 65
- Sinequan; *see* Doxepin
- Single blind study, 302
- Skin
  - burn injury to, 527–531
  - cutaneous stimulation and, 390, 405–412
    - heat and cold for, 406–411
    - sites in, 406*f*
    - vibration as, 411–412
  - Ehlers-Danlos syndrome and, 543
  - shingles and, 561–564
  - wound pain and, 592–595
- Skin-to-skin intervention, 660–661
- Sleep disorder
  - burn injury and, 529*t*
  - chronic pain and, 500
  - in cognitively impaired elderly, 701
  - pain effects on, 29
  - severe pain and, 46
  - wound pain and, 592
- Sodium bicarbonate for infant, 665–666
- Sodium ion in transduction of pain, 18
- Sodium salicylate, 133*t*
- Solubility
  - intraplasmic anesthesia and, 220–222
  - of opioids, 169
- Soma; *see* Carisoprodol
- Somatic pain, 16
  - cancer-related, 533
  - definition of, 19*t*
- Somatization, 468
- Somatoform disorder, 36, 49
- Spasm
  - fibromyalgia and, 547–548
  - pain causing, 28
- Specialist, certification of, 11–12
- Sphincter of Oddi, 581
- Spinal analgesia; *see also* Epidural analgesia; Intraspinal analgesia
  - clonidine, 337*t*
  - labor and delivery and, 619–620
- Spinal cord
  - compression of
    - cancer-related, 539
    - corticosteroids for, 312, 313, 339–340
  - injury to, 606–607
  - neuropathic pain and, 23
  - pain in infants and, 635
  - tumor of, 536*t*
- Spinal nerve, dermatomes and, 217*f*
- Spine; *see also* Back pain
  - anatomy of, 213–214, 216*t*
  - ankylosing spondylitis and, 595–596
  - arachnoiditis and, 596
  - elderly and, 679*t*
  - osteoporosis and, 574

- Spine—cont'd  
 tumor of, 533*t*  
 vertical column, 216*f*
- Splinting, 594
- Spray  
 nasal, 112  
 refrigerant, 377
- Spray and stretch technique for myofascial pain syndrome, 570
- Stadol; *see* Butorphanol
- Stanback, 149*t*
- Stanback AF Extra-Strength, 148*t*
- Standard  
 for assessment, treatment, and documentation, 730, 734*t*  
 definition of, 712
- State medical board, 9–10
- Status migraine, 556
- Steady state of opioid, 169–170
- Steroid; *see* Corticosteroid
- Stiffness, fibromyalgia and, 548
- Stigma of addiction, 51, 53
- Stimulation  
 cutaneous, 390, 405–412  
   heat and cold for, 406–411  
   sites in, 406*f*  
   vibration as, 411–412  
 dorsal column, 584  
 electric, in multiple sclerosis, 603
- Stimulus, noxious, 16
- Stocking-glove distribution of pain, 577*f*
- Stomach disorder, 136–137
- Stomal administration of opioid, 205–206, 206*t*
- Stomatitis, 601–602
- Stress, 23–32  
 chronic pain and, 501–503  
 harmful effects of, 23–22  
   on cardiovascular system, 25–26  
   on cognitive function, 28–29  
   developmental effects of, 30  
   on endocrine and metabolic system, 23–25  
   in future, 30–31  
   on gastrointestinal system, 27–28  
   on genitourinary system, 27  
   on immune system, 29–30  
   on musculoskeletal system, 27–28  
   on quality of life, 31–32  
   on respiratory system, 26–27  
 hypercoagulation and, 25  
 infant and, 635  
 posttraumatic, 468
- Stroke, pain after, 696
- Strontium chloride-89, 325, 326
- Stump pain in elderly, 694
- Subacute overdose, 269
- Subarachnoid space, 213–214
- Subarachnoid space block, 619–620
- Subcutaneous administration of opioid, 195*t*, 210–211, 211*t*, 212
- Sublimaze; *see* Fentanyl
- Sublingual administration of opioids, 195*t*, 201
- Suboccipital trigger point, 571*f*
- Substance abuse, 428–462; *see also* Addiction  
 costs, 441*f*  
 diagnostic criteria for, 435*t*, 436*t*  
 motivational tasks, 447*t*  
 patient placement, 451*t*  
 pregnancy and, 616–617
- Substance P, 22
- Sucking, nonnutritive, 659
- Sucralfate, 137
- Sucrose for infant, 659–660
- Sufentanil  
 intranasal, 203  
 intraspinal, 224, 227  
 for opioid-naïve adult, 225*t*  
 pregnancy and, 614  
 solubility of, 169
- Suicide, risk assessment, 487, 487*t*
- Sulindac, 139*t*
- Sumatriptan  
 breast feeding and, 624  
 cluster headache and, 555*t*  
 migraine and, 553
- Superficial heat and cold, 406–411
- Superior vena cava syndrome, 312, 313, 339
- Support group, 686
- Suppository; *see* Rectal administration
- Supraspinal injection, 162
- Supraspinatus trigger point, 571*f*
- Supratentorial pain, 36, 49–50
- Surgery; *see also* Perioperative analgesia; Postoperative pain  
 ambulatory, 145  
 ankylosing spondylitis and, 596  
 arthritis and, 526  
 gel pack for incisional pain, 409*f*  
 in infant, 24–25, 639, 662, 663*f*  
 low back pain and, 600  
 multiple sclerosis and, 603  
 postmastectomy pain and, 604  
 reflex sympathetic dystrophy and, 584  
 temporomandibular dysfunction and, 591
- Survey  
 “Andrew-Robert,” 38*t*, 39–40, 40*t*, 44  
 chronic pain and, 508  
 pain knowledge and attitude, 729
- Suturing, atraumatic, 395
- Swaddling of infant, 659
- Sweats with alcohol withdrawal, 457
- Sympathetic blockade, 584
- Sympathetic dystrophy, reflex, 581–584, 582*f*
- Sympathetically maintained pain, 19*t*, 330
- Symptom Checklist-90R, 519
- Synapse, 16
- Systemic drug, 302
- T
- Tabetic pain, 302
- TAC, 373
- Tachycardia, 694
- Tactile disturbance in alcohol withdrawal, 457
- Talwin; *see* Pentazocine

- Tapering of opioid, 270–271, 494–496
- Teaching; *see* Education *entries*
- Tegretol; *see* Carbamazepine
- Temporal arteritis, 695–696
- Temporomandibular joint disorder, 588–591  
sources and sites of pain, 589*f*
- Tempra, 148*t*
- Tenderness in fibromyalgia, 547
- Tendinitis, 690*t*
- Tenormin; *see* Atenolol
- Tension headache, 555*t*, 557–558
- Teratogenesis, 609  
opioids and, 614
- Terazocin, 604
- Term infant; *see also* Infant  
definition of, 627  
pain behavior in, 634
- Terminally ill patient  
antidepressants for, 310  
HIV and, 565  
nebulized opioid for, 203  
opioid for, 272  
pain assessment in, 94
- Terminology, 756–757  
about agreements, 751–752
- Testosterone, 24
- Tetracaine, 371–372, 373, 374*t*
- Tetrahydrocannabinol, 334
- Thermoregulation, 26
- Thoracic epidural analgesia, 222
- Thoracic surgery  
in elderly, 678*t*  
pain of, 605–606
- Thoracic trauma, 26
- Thoracic vertebral tumor, 536*t*
- Thorazine; *see* Chlorpromazine
- Throat, gel pack for, 409*f*
- Tick-borne disease, 600–601
- Tissue adhesive, 395
- Titration of dose  
for acetaminophen, 141  
definition of, 36  
individualization of regimen and, 121–122  
for nonsteroidal antiinflammatory drugs, 141  
of opioid, 246–249  
for elderly, 695  
patient-controlled analgesia, 253
- Tizanidine, 305*t*, 342*t*
- TLC, 373
- Tocainide, 305*t*  
elderly and, 698  
indications and dosages of, 344  
neuropathic pain and, 318, 321*t*
- Tofanil; *see* Imipramine
- Tolerance  
drug  
addiction versus, 433–434  
definition of, 50, 162, 429  
epidural analgesia and, 260–261  
methadone and, 185–186
- Tolerance—cont'd  
drug—cont'd  
misconceptions about, 163*t*  
opioid, 171–173  
switching of drug in, 253–257  
pain, high versus low, 42–43
- Tolmetin, 139*t*
- Tonocard; *see* Tocainide
- Tool, assessment, 58–99; *see also* Assessment, tools for
- Topical agent, 331–332, 331*t*  
adjuvant, 305*t*  
antiinflammatory, 331  
burn injury and, 530–531  
capsaicin, 331  
herpes zoster and, 562  
infant and, 656–657  
local anesthetic, 331–332, 371–377  
mucositis and, 602  
neuropathic pain and, 321*t*  
osteoporosis and, 575  
peripheral neuropathy and, 578  
refrigerant spray and, 377
- Toradol; *see* Ketorolac
- Total body surface area, 527
- Total knee replacement, 694
- Total quality management, 713, 714–715*t*
- Toxicity  
corticosteroid, 312  
in elderly, 697–698  
epidural local anesthetics and, 230*t*  
local anesthetic, 318, 368  
elderly and, 698  
of topical agent, 332
- Toxicology, urine, 446
- Trade name of nonopioid drugs, 138*t*
- Tramadol  
characteristics of, 190–191  
elderly and, 692
- Transcutaneous electrical nerve stimulation  
for elderly, 700  
reflex sympathetic dystrophy and, 583
- Transdermal administration of opioid,  
206–209
- Transduction, 16, 18, 22  
of antidepressant, 309*f*  
definition of, 106*f*  
illustration of, 21, 107*f*  
for local anesthetics, 319*f*  
nonsteroidal antiinflammatory drugs and, 130
- Transmission of pain, 16, 19*t*  
of antidepressant, 309*f*  
definition of, 106*f*  
illustration of, 21, 107*f*  
for local anesthetics, 319*f*  
process of, 22
- Transmucosal administration of opioid  
buccal, 201  
characteristics of, 195*t*  
of fentanyl, 202*f*, 207*f*, 209*t*  
characteristics of, 202–203

- Transmucosal administration of opioid—cont'd  
 of fentanyl—cont'd  
   for procedural pain, 378, 379*t*  
   as rescue analgesic, 245  
 gingival, 201  
 for procedural pain, 378  
 sublingual, 201
- Trauma  
 infant and, 638–639  
 needle or catheter, 233  
 spinal cord, 606–607  
 wound pain and, 592–595
- Trazodone, 305*t*, 306*t*, 307
- Treatment, misconceptions affecting, 37*t*
- Tremor in alcohol withdrawal, 457
- Trial, clinical, types of, 302
- Triavil, 699*t*
- Tricyclic antidepressant; *see* Antidepressant
- Trigeminal Neuralgia Association, 518
- Trigger for migraine, 553
- Trigger point, 569, 570, 571*f*  
 in fibromyalgia  
   identification of, 546  
   injection of, 549
- Trilisate; *see* Choline magnesium trisalicylate
- Trimester of pregnancy, 609
- Trunk pain in elderly, 679*t*
- Tumor, 531–543; *see also* Cancer-related pain
- Twelve-step program of drug treatment, 442–443, 442*t*
- Tylenol; *see* Acetaminophen
- Tylenol 3, 117, 134
- Tylox, 117, 134
- U
- Ulcer  
 aphthous, HIV and, 566–567  
 corticosteroid causing, 312  
 in elderly, 689, 698–699  
 nonsteroidal antiinflammatory drugs causing, 136, 137  
 reducing risk of, 110  
 venous, 592
- Unconscious patient, pain assessment in, 94
- Undertreatment of pain  
 in chronic nonmalignant pain, 271  
 circumcision and, 636–639  
 diagnosis of cause of pain and, 47  
 in elderly, 676–677  
 health care professional and, 4–5, 9–10  
   education for, 734, 736–737  
 in infants, 628–631  
 nurses' expectations about pain of, 44  
 postoperative, in child, 144  
 in terminally ill patient, 272  
 weaning from mechanical ventilation and, 271–272
- Unidimensional pain measures in infants, 640–642, 643*t*
- UNIPACS, 6
- Unrelieved pain, 3–4, 23–32, 24*t*
- Urecholine; *see* Bethanechol
- Urethral catheterization, atraumatic, 372*t*
- Urinary retention, 266
- Urinary retention—cont'd  
 epidural analgesia and, 230*t*  
 in child, 239
- Urine toxicology, 446
- Urologic surgery in elderly, 678*t*
- Uterine contraction, postpartum, 622
- Uterus  
 cesarean section and, 622–623  
 involution of, 609
- V
- Vaginal administration  
 of opioid, 206  
 of opioids, 195*t*
- Valium; *see* Diazepam
- Valproate  
 indications and dosages of, 342*t*  
 neuropathic pain and, 321*t*
- Valproic acid, 305*t*  
 adverse effects of, 323  
 for child, 341*t*  
 cluster headache and, 556*t*  
 migraine and, 555*t*  
 overview of, 322
- Vanquish, 149*t*
- Varicella-zoster virus, 561–564, 561*f*
- VAS; *see* Visual analog scale
- Vascular disease in elderly, 696
- Vascular surgery  
 in elderly, 678*t*  
 hypercoagulability and, 25–26
- Vastis lateralis injection site, 393*f*
- Vena cava syndrome, superior, 312  
 corticosteroids for, 312, 313, 339
- Venlafaxine, 305*t*, 306*t*
- Venous ulcer, 592
- Ventilation, mechanical, weaning from, 271–272
- Ventrogluteal injection site, 392*f*
- Veracept; *see* Nelfinavir
- Verapamil  
 cluster headache and, 556*t*  
 migraine and, 555*t*
- Versed; *see* Midazolam
- Vertebral column, anatomy of, 213–214, 216*f*
- Vertebral fracture, 574
- Vertebral tumor, 536*t*
- Very-low-birth-weight infant, 627
- Vicodin, 117, 134
- Vicoprofen, 134
- Video tapes pain management, 738
- Viracept; *see* Nelfinavir
- Viral infection  
 HIV, 564–568, 566*f*  
   peripheral neuropathy in, 576  
 varicella-zoster, 561–564, 561*f*
- Visceral pain, 16  
 cancer-related, 534*t*  
 definition of, 19*t*
- Visual analog scale (VAS), 62  
 definition of, 36

- Visual analog scale (VAS)—cont'd  
 horizontal, 62*f*  
 numerical scale versus, 65–66
- Visual disturbance in alcohol withdrawal, 457
- Vital sign  
 fifth, 3  
 graphic record of, 735  
 infant and, 633
- Vitamin D, osteoporosis and, 575
- Vomiting  
 alcohol withdrawal and, 457  
 elderly and, 695  
 ergotamine withdrawal and, 559  
 migraine and, 553  
 opioids causing, 261, 262*t*–263*t*
- W
- Weaning  
 from mechanical ventilation, 271–272  
 from morphine in burn injury, 530  
 from opioid in infant, 632
- Web sites  
 for addiction treatment, 462–463  
 health-related, 749–750*t*
- Whipple procedure, 258–259
- WHO analgesic ladder, 115–119, 117*f*, 539, 541
- Wigraine; *see* Ergotamine
- Williams & Wilkins Complete Library on Pain, 6
- Wisconsin Cancer Pain Initiative, 6, 11, 274
- Withdrawal  
 alcohol, 457  
 chronic pain and, 494–496  
 corticosteroid, 312  
 infant and, 631
- Withholding of treatment; *see also* Undertreatment of pain  
 in chronic nonmalignant pain, 271  
 opioid, 271–272  
 in terminally ill patient, 272  
 weaning from mechanical ventilation and, 271–272
- Wong-Baker faces pain rating scale, 63, 66, 67  
 cultural differences and, 98
- World Health Organization  
 analgesic ladder, 115–119, 117*f*, 539, 541  
*Cancer Pain Relief* published by, 5  
 clinical practice guidelines of, 7
- Wound pain, 592–595, 593*t*
- Written agreement, 751–755
- Z
- Zantac; *see* Ranitidine
- Zogmig; *see* Zolmitriptan
- Zolmitriptan, 554*t*
- Zoster ophthalmicus, 562
- Z-track method of intramuscular injection, 391–394, 394*f*